ocular therapeutix, inc · ocular therapeutix, inc form s-3 (securities registration statement...
TRANSCRIPT
![Page 1: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/1.jpg)
OCULAR THERAPEUTIX, INC
FORM S-3(Securities Registration Statement (simplified form))
Filed 04/01/19
Address 24 CROSBY DRIVE
BEDFORD, MA, 01730Telephone 781-895-3235
CIK 0001393434Symbol OCUL
SIC Code 2834 - Pharmaceutical PreparationsIndustry Pharmaceuticals
Sector HealthcareFiscal Year 12/31
http://www.edgar-online.com© Copyright 2020, EDGAR Online, a division of Donnelley Financial Solutions. All Rights Reserved.
Distribution and use of this document restricted under EDGAR Online, a division of Donnelley Financial Solutions, Terms of Use.
![Page 2: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/2.jpg)
UsetheselinkstorapidlyreviewthedocumentTABLEOFCONTENTS
TableofContents
AsfiledwiththeSecuritiesandExchangeCommissiononApril1,2019
RegistrationNo.333-
UNITEDSTATESSECURITIESANDEXCHANGECOMMISSION
Washington,D.C.20549
FORMS-3REGISTRATIONSTATEMENT
UNDERTHESECURITIESACTOF1933
OCULARTHERAPEUTIX,INC.(ExactNameofRegistrantasSpecifiedinItsCharter)
Delaware(StateorOtherJurisdictionofIncorporationorOrganization)
20-5560161(I.R.S.Employer
IdentificationNumber)
15CrosbyDriveBedford,MA01730(781)357-4000
(Address,IncludingZipCode,andTelephoneNumber,IncludingAreaCode,ofRegistrant'sPrincipalExecutiveOffices)
AntonyMattessichPresidentandChiefExecutiveOfficer
OcularTherapeutix,Inc.15CrosbyDrive
Bedford,MA01730(781)357-4000
(Name,Address,IncludingZipCode,andTelephoneNumber,IncludingAreaCode,ofAgentforService)
Copyto:
BrianA.Johnson,Esq.WilmerHale
7WorldTradeCenter250GreenwichStreet
NewYork,NewYork10007(212)230-8800
Approximatedateofcommencementofproposedsaletothepublic:Fromtimetotimeaftertheeffectivedatehereof.
IftheonlysecuritiesbeingregisteredonthisFormarebeingofferedpursuanttodividendorinterestreinvestmentplans,pleasecheckthefollowingbox.o
IfanyofthesecuritiesbeingregisteredonthisFormaretobeofferedonadelayedorcontinuousbasispursuanttoRule415undertheSecuritiesActof1933,otherthansecuritiesofferedonlyinconnectionwithdividendorinterestreinvestmentplans,checkthefollowingbox.ý
IfthisFormisfiledtoregisteradditionalsecuritiesforanofferingpursuanttoRule462(b)undertheSecuritiesAct,pleasecheckthefollowingboxandlisttheSecuritiesActregistrationstatementnumberoftheearliereffectiveregistrationstatementforthesameoffering.o
IfthisFormisapost-effectiveamendmentfiledpursuanttoRule462(c)undertheSecuritiesAct,checkthefollowingboxandlisttheSecuritiesActregistrationstatementnumberoftheearliereffectiveregistrationstatementforthesameoffering.o
IfthisFormisaregistrationstatementpursuanttoGeneralInstructionI.D.orapost-effectiveamendmenttheretothatshallbecomeeffectiveuponfilingwiththeCommissionpursuanttoRule462(e)undertheSecuritiesAct,checkthefollowingbox.o
IfthisFormisapost-effectiveamendmenttoaregistrationstatementfiledpursuanttoGeneralInstructionI.D.filedtoregisteradditionalsecuritiesoradditionalclassesofsecuritiespursuanttoRule413(b)undertheSecuritiesAct,checkthefollowingbox.o
![Page 3: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/3.jpg)
Indicatebycheckmarkwhethertheregistrantisalargeacceleratedfiler,anacceleratedfiler,anon-acceleratedfiler,smallerreportingcompany,oranemerginggrowthcompany.Seethedefinitionsof"largeacceleratedfiler,""acceleratedfiler,""smallerreportingcompany,"and"emerginggrowthcompany"inRule12b-2oftheExchangeAct.
Ifanemerginggrowthcompany,indicatebycheckmarkiftheregistranthaselectednottousetheextendedtransitionperiodforcomplyingwithanyneworrevisedfinancialaccountingstandardsprovidedpursuanttoSection7(a)(2)(B)oftheSecuritiesAct.ý
CALCULATIONOFREGISTRATIONFEE
Titleofeachclassofsecuritiestoberegistered
AmounttobeRegistered(1)
ProposedMaximumOfferingPricePer
Unit(2)
ProposedMaximumAggregateOffering
Price(2) Amountof
RegistrationFee
CommonStock,$0.0001parvaluepershare 5,769,232(3) $3.94 $22,730,774.08 $2,754.97
CommonStock,$0.0001parvaluepershare 3,804,788(4) $3.94 $14,990,864.72 $1,816.89
(1) Thesharesofcommonstockwillbeofferedforresalebythesellingstockholders.PursuanttoRule416undertheSecuritiesAct,thisRegistrationStatementalsorelatestoanindeterminatenumberofadditionalsharesofcommonstocktobeissuedasaresultofstocksplits,stockdividendsorsimilartransactionswithrespecttothesecuritiesbeingregisteredpursuanttothisRegistrationStatement.
(2) EstimatedsolelyforpurposesofcalculatingtheregistrationfeepursuanttoRule457(c)undertheSecuritiesAct,basedonaverageofhighandlowpricepershareofthecommonstockasreportedontheNasdaqGlobalMarketonMarch25,2019.
(3) Consistsofsharesofcommonstockissuableupontheconversionofseniorsubordinatedconvertiblenotesissuedbytheregistranttoasellingstockholderandbasedontheinitialconversionrateof153.8462sharesofcommonstockper$1,000principalamountoftheoutstandingseniorsubordinatedconvertiblenotesoftheRegistrant,whichisequaltoaninitialconversionpriceofapproximately$6.50pershareofcommonstock.
(4) Consistsofissuedandoutstandingsharesofcommonstockheldbythesellingstockholders.
TheRegistrantherebyamendsthisRegistrationStatementonsuchdateordatesasmaybenecessarytodelayitseffectivedateuntiltheRegistrantshallfileafurtheramendmentwhichspecificallystatesthatthisRegistrationStatementshallthereafterbecomeeffectiveinaccordancewithSection8(a)oftheSecuritiesActof1933oruntiltheRegistrationStatementshallbecomeeffectiveonsuchdateastheCommission,actingpursuanttosaidSection8(a),maydetermine.
Largeacceleratedfilero Acceleratedfilerý Non-acceleratedfilero SmallerreportingcompanyýEmerginggrowthcompanyý
![Page 4: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/4.jpg)
TableofContents
Theinformationinthispreliminaryprospectusisnotcompleteandmaybechanged.ThesellingstockholdersnamedinthispreliminaryprospectusmaynotsellthesesecuritiesuntiltheregistrationstatementfiledwiththeSecuritiesandExchangeCommissioniseffective.Thispreliminaryprospectusisnotanoffertosellthesesecuritiesandthesellingstockholdersnamedinthispreliminaryprospectusisnotsolicitingofferstobuythesesecuritiesinanyjurisdictionwheresuchofferorsaleisnotpermitted.
SUBJECTTOCOMPLETION,DATEDAPRIL1,2019
PROSPECTUS
9,574,020SHARESOFCOMMONSTOCK
Thisprospectusrelatestotheresale,fromtimetotime,ofupto9,574,020sharesofourcommonstock,allofwhicharebeingofferedbythesellingstockholdersnamedinthisprospectus,whichsharesinclude3,804,788sharesofourcommonstockthatareissuedandoutstandingandupto5,769,232sharesofourcommonstockissuableupontheconversionofoutstandingseniorsubordinatedconvertiblenotes.TheseniorsubordinatedconvertiblesnotesweresoldbyustoasellingstockholderinconnectionwithaprivateplacementpursuanttoRule506ofRegulationDpromulgatedundertheSecuritiesActof1933,asamended,ortheSecuritiesAct.Weareregisteringthesesharesonbehalfofthesellingstockholderstobeofferedandsoldbythemfromtimetotime.
Wearenotsellinganysharesofourcommonstockunderthisprospectusandwillnotreceiveanyproceedsfromthesaleofthesharesofourcommonstockbythesellingstockholders.
Thesellingstockholdersidentifiedinthisprospectus,ortheirpledgees,assignees,donees,transfereesorothersuccessors-in-interest,mayofferthesharesfromtimetotimethroughpublicorprivatetransactionsatprevailingmarketprices,atpricesrelatedtoprevailingmarketpricesoratprivatelynegotiatedprices.
OurcommonstockistradedontheNasdaqGlobalMarket,orNasdaq,underthesymbol"OCUL."OnMarch29,2019,theclosingsalepriceofourcommonstockonNasdaqwas$3.97pershare.Youareurgedtoobtaincurrentmarketquotationsforourcommonstock.
Investinginourcommonstockinvolvesahighdegreeofrisk.See"RiskFactors"beginningonpage3.
NeithertheSecuritiesandExchangeCommissionnoranystatesecuritiescommissionhasapprovedordisapprovedofthesesecuritiesordeterminedifthisprospectusistruthfulorcomplete.Anyrepresentationtothecontraryisacriminaloffense.
Thedateofthisprospectusis,2019.
![Page 5: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/5.jpg)
TableofContents
TABLEOFCONTENTS
ABOUTTHISPROSPECTUS
Youshouldcarefullyreadthisprospectusandtheinformationsetforthundertheheading"WhereYouCanFindMoreInformation"onpage16.Neitherwenorthesellingstockholdershaveauthorizedanyonetoprovideyouwithinformationdifferentfromthatcontainedorincorporatedbyreferenceinthisprospectus.Ifanyoneprovidesyouwithdifferentorinconsistentinformation,youshouldnotrelyonit.Thesellingstockholdersareofferingtosell,andseekingofferstobuy,sharesofourcommonstockonlyinjurisdictionswheresuchoffersandsalesarepermitted.Nooneismakingofferstosellorseekingofferstobuysharesofcommonstockinanyjurisdictionwheresuchoffersorsalesarenotpermitted.Theinformationappearinginthisprospectusisaccurateonlyasofthedateonthefrontcoverofthisprospectus,regardlessofthetimeofdeliveryofthisprospectusorofanysaleofcommonstock.Ourbusiness,financialcondition,resultsofoperationsandprospectsmayhavechangedsincesuchdate.
i
AboutthisProspectus i
ProspectusSummary 1
TheOffering 2
RiskFactors 3
CautionaryNoteRegardingForward-LookingInformation 4
StatementRegardingIndustryandMarketData&Trademarks 5
UseOfProceeds 6
SellingStockholders 7
DescriptionofCapitalStock 10
PlanOfDistribution 14
LegalMatters 16
Experts 16
WhereYouCanFindMoreInformation 16
IncorporationOfCertainDocumentsByReference 16
![Page 6: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/6.jpg)
TableofContents
PROSPECTUSSUMMARY
This summary highlights selected information appearing elsewhere in this prospectus and in the documents incorporated herein by reference and doesnot contain all of the information that you should consider before investing in our common stock. You should read the entire prospectus carefully, especiallythe risks of investing in our common stock discussed under "Risk Factors" beginning on page 3, the information incorporated herein by reference and theexhibits to the registration statement which this prospectus is a part.
Unless the context otherwise indicates, references in this prospectus to "we," "our" and "us" refer, collectively, to Ocular Therapeutix, Inc., aDelaware corporation, and its consolidated subsidiary.
OcularTherapeutix,Inc.
Weareabiopharmaceuticalcompanyfocusedontheformulation,developmentandcommercializationofinnovativetherapiesfordiseasesandconditionsoftheeyeusingourproprietary,bioresorbablehydrogelplatformtechnology.Weusethistechnologytotailordurationandamountofdeliveryofarangeoftherapeuticagentsofvaryingdurationinourproductcandidates.
Wecurrentlyincorporatetherapeuticagentsthathavepreviouslyreceivedregulatoryapproval,includingsmallmoleculesandproteins,intoourhydrogeltechnologywiththegoalofprovidinglocalprogrammed-releaseddeliveryofdrugtotheeye.Webelievethatourlocalprogrammed-releasetechnologyhasthepotentialtotreatconditionsanddiseasesofboththefrontandthebackoftheeyeandcanbeadministeredthrougharangeofdifferentmodalitiesincludingintracanalicularinserts,intracameralimplantsandintravitrealimplants.Wehaveproductsandproductcandidatesinclinicalandpreclinicaldevelopmentapplyingthistechnologytotreatpost-surgicalocularpainandinflammation,allergicconjunctivitis,dryeyedisease,glaucomaandocularhypertension,andwetage-relatedmaculardegeneration,orwetAMD,amongotherconditions.
Inadditiontoourfocusonformulating,developingandcommercializinginnovativetherapiesfordiseasesandconditionsoftheeye,wearealsoassessingthepotentialuseofourhydrogelplatformtechnologyinotherareasofthebody.
CorporateInformation
Ourprincipalexecutiveofficesandresearchanddevelopmentoperationsarelocatedat15CrosbyDrive,Bedford,MA01730,andourtelephonenumberis(781)357-4000.Ourmanufacturingoperationsarelocatedat36CrosbyDrive,Bedford,MA01730.
1
![Page 7: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/7.jpg)
TableofContents
THEOFFERING
2
CommonStockofferedbysellingstockholders 9,574,020shares
Termsoftheoffering
Thesellingstockholdersidentifiedinthisprospectus,ortheirpledgees,assignees,donees,transfereesorothersuccessors-in-interest,mayofferthesharesfromtimetotimethroughpublicorprivatetransactionsatprevailingmarketprices,atpricesrelatedtoprevailingmarketpricesoratprivatelynegotiatedprices.Youshouldreadthe"PlanofDistribution"sectionbeginningonpage14foradditionalinformationonhowthesellingstockholdersmayconductsalesofourcommonstock.
Useofproceeds
Wewillnotreceiveanyproceedsfromthesaleofsharesofcommonstockofferedhereby.
RiskFactors
Youshouldreadthe"RiskFactors"sectionbeginningonpage3ofthisprospectusforadiscussionoffactorstoconsidercarefullybeforedecidingtoinvestinsharesofourcommonstock.
NasdaqGlobalMarketsymbol
"OCUL"
![Page 8: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/8.jpg)
TableofContents
RISKFACTORS
Investinginourcommonstockinvolvesahighdegreeofrisk.YoushouldcarefullyconsidertherisksanduncertaintiesdescribedinourfilingswiththeSecuritiesandExchangeCommission,ortheSEC,includingourmostrecentAnnualReportonForm10-K,asrevisedorsupplementedbyoursubsequentQuarterlyReportsonForm10-Q,whichareincorporatedbyreferencehereinintheirentirety,togetherwithotherinformationinthisprospectus,aswellasanyapplicableprospectussupplement,andtheinformationanddocumentsincorporatedbyreferenceinthisprospectusbeforemakinganinvestmentdecisionpursuanttothisprospectus.Ourbusiness,financialconditionandresultsofoperationscouldbemateriallyandadverselyaffectedbyanyoralloftheserisksorbyadditionalrisksanduncertaintiesnotpresentlyknowntousorthatwecurrentlydeemimmaterialthatmayadverselyaffectusinthefuture.Inanysuchcase,thetradingpriceofourcommonstockcouldfall,andyoumayloseallorpartofthemoneyyoupaidtobuyourcommonstock.
3
![Page 9: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/9.jpg)
TableofContents
CAUTIONARYNOTEREGARDINGFORWARD-LOOKINGINFORMATION
Thisprospectusandtheinformationincorporatedbyreferencehereininclude"forward-lookingstatements"withinthemeaningofSection27AoftheSecuritiesActandSection21EoftheSecuritiesExchangeActof1934,asamended,ortheExchangeAct,thatinvolvesubstantialrisksanduncertainties.Allstatements,otherthanstatementsofhistoricalfacts,containedinthisprospectusandtheinformationincorporatedbyreferenceherein,includingstatementsregardingourstrategy,futureoperations,futurefinancialposition,futurerevenues,projectedcosts,prospects,plansandobjectivesofmanagement,areforward-lookingstatements.Thewords"anticipate,""believe,""estimate,""expect,""intend,""may,""might,""plan,""predict,""project,""target,""potential,""goals,""will,""would,""could,""should,""continue"andsimilarexpressionsareintendedtoidentifyforward-lookingstatements,althoughnotallforward-lookingstatementscontaintheseidentifyingwords.
Wemaynotactuallyachievetheplans,intentionsorexpectationsdisclosedinourforward-lookingstatements,andyoushouldnotplaceunduerelianceonourforward-lookingstatements.Actualresultsoreventscoulddiffermateriallyfromtheplans,intentionsandexpectationsdisclosedintheforward-lookingstatementswemake.Wehaveincludedimportantfactorsinthecautionarystatementsincludedorincorporatedinthisprospectus,particularlyundertheheading"RiskFactors,"thatwebelievecouldcauseactualresultsoreventstodiffermateriallyfromtheforward-lookingstatementsthatwemake.Ourforward-lookingstatementsdonotreflectthepotentialimpactofanyfutureacquisitions,mergers,dispositions,jointventures,collaborationsorinvestmentswemaymake.Youshouldreadthisprospectusandthedocumentsincorporatedbyreferenceinthisprospectuscompletelyandwiththeunderstandingthatouractualfutureresultsmaybemateriallydifferentfromwhatweexpect.Wedonotassumeanyobligationtoreviseorupdateanyforward-lookingstatements,whetherasaresultofnewinformation,futureeventsorotherwise,exceptasrequiredbyapplicablelaw.
4
![Page 10: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/10.jpg)
TableofContents
STATEMENTREGARDINGINDUSTRYANDMARKETDATA&TRADEMARKS
Weobtainedthemarket,industryandcompetitivepositiondatacontainedinorincorporatedbyreferenceintothisprospectusfromourowninternaldataandestimatesandavarietyofthird-partysources,includingindependentindustrypublications,governmentpublications,reportsbymarketresearchfirmsorotherpublishedindependentsources.Ourinternaldataandestimatesarebaseduponinformationobtainedfromtradeandbusinessorganizationsandothercontactsinthemarketsinwhichweoperateandourmanagement'sunderstandingofindustryconditions.
Thisprospectusandthedocumentsincorporatedbyreferencehereincontainreferencestoourtrademarksandservicemarksandtothosebelongingtootherentities.Solelyforconvenience,trademarksandtradenamesreferredtointhisprospectusandthedocumentsincorporatedbyreferencehereinmayappearwithoutthe®or™symbols,butsuchreferencesarenotintendedtoindicate,inanyway,thatwewillnotassert,tothefullestextentunderapplicablelaw,ourrightsortherightsoftheapplicablelicensortothesetrademarksandtradenames.Wedonotintendouruseordisplayofothercompanies'tradenames,trademarksorservicemarkstoimplyarelationshipwith,orendorsementorsponsorshipofusby,anyothercompanies.
5
![Page 11: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/11.jpg)
TableofContents
USEOFPROCEEDS
Wewillnotreceiveanyproceedsfromthesaleofthesharesofourcommonstockcoveredbythisprospectus.Allproceedsfromthesaleoftheshareswillbefortheaccountofthesellingstockholdersnamedherein.
Thesellingstockholderswillpayanyunderwritingdiscountsandcommissionsandexpensesincurredbythesellingstockholdersforbrokerage,accounting,taxorlegalservicesoranyotherexpensesincurredbythesellingstockholdersindisposingofthesharescoveredbythisprospectus.Wewillbearallothercosts,feesandexpensesincurredineffectingtheregistrationofthesharescoveredbythisprospectus,including,withoutlimitation,allregistrationandfilingfees,Nasdaqlistingfees,andfeesandexpensesofourcounselandouraccountants.
6
![Page 12: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/12.jpg)
TableofContents
SELLINGSTOCKHOLDERS
Thesharesofcommonstockcoveredbythisprospectusconsistof5,769,232sharesofcommonstockissuableupontheconversionofaseniorsubordinatedconvertiblenote,datedMarch1,2019,betweenusandCap1LLC,orCap1,anaffiliateofSummerRoad,LLC,orSummerRoad,inaccordancewiththetermstherein,and3,804,788additionaloutstandingsharesofcommonstockheldbyCap1andanotheraffiliateofSummerRoad,orthesellingstockholders,asofMarch1,2019,allofwhichwehaveagreedtousecommerciallyreasonableefforttoregisterinaccordancewitharegistrationrightsagreement.Foradditionalinformationregardingtheseniorsubordinatedconvertiblenoteandtherelatedregistrationrightsagreement,see"—Description of Transactions with the SellingStockholders "below.Weareregisteringthesharesofcommonstocktopermitthesellingstockholderstoofferthesharesforresalefromtimetotime.
Toourknowledgeandexceptasnotedunderthecaptiontitled"—Description of Transactions with the Selling Stockholders "below,thesellingstockholdersdonothave,andwithinthepastthreeyearshavenothad,anyposition,officeorothermaterialrelationshipwithusoranyofourpredecessorsoraffiliates.
Thefollowingtablesetsforth,toourknowledge,certaininformationaboutthesellingstockholdersasofMarch15,2019.Theinformationinthetablebelowwithrespecttothesellingstockholdershasbeenobtainedfromthesellingstockholders.Thepercentageofbeneficialownershipisbasedupon42,836,572sharesofcommonstockoutstandingonMarch15,2019.
BeneficialownershipisdeterminedinaccordancewiththerulesoftheSECandincludesvotingorinvestmentpowerwithrespecttoshares.Sharesofcommonstockthattheholderhastherighttoacquireupontheexerciseorconversionofderivativesecuritieswithin60daysafterMarch15,2019aredeemedoutstandingforcomputingthepercentageofownershipofthepersonholdingsuchderivativesecuritiesbutarenotdeemedoutstandingforcomputingthepercentageownershipofanyotherpersons.Unlessotherwiseindicatedbelow,toourknowledge,allpersonsnamedinthetablehavesolevotingandinvestmentpowerwithrespecttotheirsharesofcommonstock,excepttotheextentauthorityissharedbyspousesunderapplicablelaw.Theinclusionofanysharesinthistabledoesnotconstituteanadmissionofbeneficialownershipforthepersonnamedbelow.
7
SharesofCommonStocktobe
BeneficiallyOwnedAfterOffering(1)
SharesofCommonStockBeneficially
OwnedPriortoOffering
NumberofSharesofCommonStockBeing
Offered
NameofSellingStockholders Number Percentage Number Percentage Cap1LLC(2) 8,946,532(3) 18.4% 8,946,532 0 —EastRiverPartnersLtd.(2) 627,488 1.5% 627,488 0 —
(1) Wedonotknowwhenorinwhatamountsthesellingstockholdersmayoffersharesforsale.Thesellingstockholdersmightnotsellanyofthesharesofferedbythisprospectus.Becausethesellingstockholdersmayofferallorsomeofthesharespursuanttothisoffering,andbecausetherearecurrentlynoagreements,arrangementsorunderstandingswithrespecttothesaleofanyofthesharescoveredbythisprospectus,wecannotestimatethenumberofthesharesthatwillbeheldbythesellingstockholdersaftercompletionoftheoffering.However,forpurposesofthistable,wehaveassumedthat,aftercompletionoftheoffering,noneofthesharescoveredbythisprospectuswillbeheldbythesellingstockholders.
(2) SummerRoadisafamilyofficeofthesamefamilyunderInvestmentAdvisersActof1940Rule202(a)(11)(G)-1,ortheFamilyOfficeRule.Pursuanttoinvestmentmanagementagreementsbetweenitselfandits"FamilyClients"(asdefinedintheFamilyOfficeRule),SummerRoadexercisesvotinganddispositivepowerwithrespecttoourcommonstockheldbyeachofthe
![Page 13: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/13.jpg)
TableofContents
DescriptionofTransactionswiththeSellingStockholders
Private Placement of Convertible Debt
OnFebruary21,2019,ortheAgreementDate,weenteredintoaNotePurchaseAgreement,orthePurchaseAgreement,withCap1toissueandselltoCap1unsecuredseniorsubordinatedconvertiblenotes,ortheNotes,intheoriginalaggregateprincipalamountof$37.5million.TheissuanceandsaleoftheNotesoccurredonMarch1,2019,ortheClosingDate.TheNoteswereissuedinrelianceontheexemptionfromregistrationsetforthinRule506ofRegulationDpromulgatedundertheSecuritiesAct.InaccordancewiththePurchaseAgreement,eachNoteaccruesinterestatarateof6%ofitsoutstandingprincipalamountperannum,payableatmaturity.ThematuritydateofeachNoteisMarch1,2026,unlessearlierconverted,repurchasedorredeemedasdescribedbelow.
HoldersoftheNotesmay,subjecttocertainconditions,convertallorpartoftheoutstandingprincipalamountoftheirNotesintosharesofourcommonstock,providedthatnoconversionresultsintheholderoritsaffiliatesbeneficiallyowningmorethan19.99%ofourissuedandoutstandingcommonstock.TheconversionratefortheNotesisinitially153.8462sharesofourcommonstockper$1,000principalamountoftheNotes,whichisequivalenttoaninitialconversionpriceofapproximately$6.50pershare.Theconversionrateissubjecttoadjustmentincustomarycircumstancessuchasstocksplitsorsimilarchangestoourcapitalization.Atourelection,wemaychoosetomakesuchconversionpaymentincash,insharesofourcommonstock,orinacombinationthereof.UponanyconversionofanyNote,weareobligatedtomakeacashpaymenttotheholderofsuchNoteforanyinterestaccruedbutunpaidontheprincipalamountconverted.Upontheoccurrenceofa"CorporateTransaction"(asdefinedintheNotes),theholderofaNoteisentitled,atsuchholder'soption,toconvertalloftheoutstandingprincipalamountoftheNoteinaccordancewiththeforegoingandreceiveanadditional"make-whole"cashpaymentinaccordancewithatablesetforthineachNote.
UpontheoccurrenceofaCorporateTransaction,eachholderofaNotehastheoptiontorequireustorepurchaseallorpartoftheoutstandingprincipalamountofsuchNoteatarepurchasepriceequalto100%oftheoutstandingprincipalamountoftheNotetoberepurchased,plusaccruedandunpaidinterestto,butexcluding,therepurchasedate.
OnorafterMarch1,2022,ifthelastreportedsalepriceofourcommonstockhasbeenatleast130%oftheconversionratethenineffectfortwentyoftheprecedingthirtytradingdays(includingthelasttradingdayofsuchperiod),weareentitled,atouroption,toredeemallorpartoftheoutstandingprincipalamountoftheNotes,onaproratabasis,atanoptionalredemptionpriceequalto100%oftheoutstandingprincipalamountoftheNotestoberedeemed,plusaccruedandunpaidinterestto,butexcluding,theoptionalredemptiondate.
ThePurchaseAgreementcontainscustomaryrepresentationsandwarrantiesbyusandCap1.ThePurchaseAgreementdoesnotincludeanyfinancialcovenants.OurobligationsunderthePurchaseAgreementandtheNotesaresubjecttoaccelerationupontheoccurrenceofspecifiedeventsofdefault,includinginthecaseofadefaultorbreachofcertaincontractsmaterialtous,andthedelistingandderegistrationofourcommonstock.
8
FamilyClients.SummerRoad'smailingaddressis655MadisonAvenue,19thFloor,NewYork,NewYork10065Attn:RichardA.Silerberg,ChiefOperatingOfficer.
(3) Includes5,769,232sharesofourcommonstocksubjecttoissuancepursuanttotheseniorsubordinatedconvertiblenote.
![Page 14: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/14.jpg)
TableofContents
Registration Rights Agreement
InconnectionwiththeexecutionofthePurchaseAgreementandtheissuanceandsaleoftheNotesthereunder,weandCap1enteredintoaregistrationrightsagreement,ortheRegistrationRightsAgreement,ontheClosingDate.UnderthetermsoftheRegistrationRightsAgreementandsubjecttospecifiedexceptions,weareobligatedtousecommerciallyreasonableefforts,atourexpense,tofilewiththeSECaresaleregistrationstatementtowhichthisprospectusrelates,ortheRegistrationStatement,toregisterourcommonstockunderlyingtheNotesandcertainotherregistrablesecuritieswithin30daysoftheClosingDateandtohavetheSECdeclaretheRegistrationStatementeffectivewithin90daysoftheClosingDate.WewillbefurtherobligatedtousecommerciallyreasonableeffortstocausetheRegistrationStatementtoremaincontinuouslyeffectiveuntiltheearlierofthedateswhenallsecuritiesregistrableundertheRegistrationRightsAgreement(i)havebeensoldor(ii)maybesoldwithoutrestriction,subjecttocertainconditions,pursuanttoRule144promulgatedundertheSecuritiesAct.
9
![Page 15: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/15.jpg)
TableofContents
DESCRIPTIONOFCAPITALSTOCK
Thefollowingdescriptionofourcapitalstockandprovisionsofourcertificateofincorporationandby-lawsaresummariesandarequalifiedbyreferencetoourcertificateofincorporation,ourby-lawsandapplicableprovisionsofDelawarecorporatelaw.Wehavefiledcopiesofourcertificateofincorporationandourby-lawswiththeSECasexhibitstotheRegistrationStatement.
Ourauthorizedcapitalstockconsistsof100,000,000sharesofourcommonstock,parvalue$0.0001pershare,and5,000,000sharesofourpreferredstock,parvalue$0.0001pershare,allofwhichpreferredstockisundesignated.
AsofMarch15,2019,wehadissuedandoutstanding42,836,572sharesofourcommonstockandnosharesofourpreferredstock.
CommonStock
Voting Rights. Holdersofourcommonstockareentitledtoonevoteforeachshareheldonallmatterssubmittedtoavoteofstockholdersanddonothavecumulativevotingrights.Eachelectionofdirectorsbyourstockholderswillbedeterminedbyapluralityofthevotescastbythestockholdersentitledtovoteontheelection.Ingeneral,except(1)fortheelectionofdirectors,(2)asdescribedbelowunder"—ProvisionsofOurCertificateofIncorporationandBy-lawsandDelawareLawThatMayHaveAnti-TakeoverEffects—Super-MajorityVoting,"(3)inthefuturetotheextentthatwehavetwoormoreclassesorseriesofstockoutstandingwithseparatevotingrightsand(4)asotherwiserequiredbylaw,anymattertobevotedonbyourstockholdersatanymeetingisdecidedbythevoteoftheholdersofamajorityinvotingpowerofthevotescastbytheholdersofsharesofourstockpresentorrepresentedatthemeetingandvotingaffirmativelyornegativelyonsuchmatter.
Dividends. Holdersofcommonstockareentitledtoreceiveproportionatelyanydividendsasmaybedeclaredbyourboardofdirectors,subjecttoanypreferentialdividendrightsofoutstandingpreferredstock.
Liquidation and Dissolution. Intheeventofourliquidationordissolution,theholdersofourcommonstockareentitledtoreceiveproportionatelyallassetsavailablefordistributiontostockholdersafterthepaymentofalldebtsandotherliabilitiesandsubjecttothepriorrightsofanyofouroutstandingpreferredstock.
Other Rights. Holdersofourcommonstockhavenopreemptive,subscription,redemptionorconversionrights.Therights,preferencesandprivilegesofholdersofourcommonstockaresubjecttoandmaybeadverselyaffectedbytherightsoftheholdersofsharesofanyseriesofourpreferredstockthatwemaydesignateandissueinthefuture.
Transfer Agent and Registrar. ComputershareTrustCompany,Inc.istransferagentandregistrarforourcommonstock.
Nasdaq Global Market. OurcommonstockislistedonNasdaqunderthesymbol"OCUL."
PreferredStock
Underthetermsofourcertificateofincorporation,ourboardofdirectorsisauthorizedtoissuesharesofourpreferredstockinoneormoreserieswithoutstockholderapproval,subjecttoanylimitationsimposedbyapplicableNasdaqrules.Ourboardofdirectorshasthediscretiontodeterminetherights,preferences,privilegesandrestrictions,includingvotingrights,dividendrights,conversionrights,redemptionprivilegesandliquidationpreferences,ofeachseriesofpreferredstock.
Thepurposeofauthorizingourboardofdirectorstoissuepreferredstockanddetermineitsrightsandpreferencesistoeliminatedelaysassociatedwithastockholdervoteonspecificissuances.The
10
![Page 16: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/16.jpg)
TableofContents
issuanceofpreferredstock,whileprovidingflexibilityinconnectionwithpossibleacquisitions,futurefinancingsandothercorporatepurposes,couldhavetheeffectofmakingitmoredifficultforathirdpartytoacquire,orcoulddiscourageathirdpartyfromseekingtoacquire,amajorityofouroutstandingvotingstock.Currently,wehavenosharesofpreferredstockoutstanding.
EffectsofAuthorizedbutUnissuedStock
Wehavesharesofcommonstockandpreferredstockavailableforfutureissuancewithoutstockholderapproval,subjecttoanylimitationsimposedbythelistingstandardsofNasdaq.Wemayutilizetheseadditionalsharesforavarietyofcorporatepurposes,includingforfuturepublicofferingstoraiseadditionalcapitalorfacilitatecorporateacquisitionsorforpaymentasadividendonourcapitalstock.Theexistenceofunissuedandunreservedcommonstockandpreferredstockmayenableourboardofdirectorstoissuesharestopersonsfriendlytocurrentmanagementortoissuepreferredstockwithtermsthatcouldhavetheeffectofmakingitmoredifficultforathirdpartytoacquire,orcoulddiscourageathirdpartyfromseekingtoacquire,acontrollinginterestinourcompanybymeansofamerger,tenderoffer,proxycontestorotherwise.Inaddition,ifweissuepreferredstock,theissuancecouldadverselyaffectthevotingpowerofholdersofcommonstockandthelikelihoodthatsuchholderswillreceivedividendpaymentsandpaymentsuponliquidation.
ProvisionsofOurCertificateofIncorporationandBy-lawsandDelawareLawThatMayHaveAnti-TakeoverEffects
Delaware Law
WearesubjecttoSection203oftheDelawareGeneralCorporationLaw,ortheDGCL.Subjecttocertainexceptions,Section203preventsapubliclyheldDelawarecorporationfromengagingina"businesscombination"withany"interestedstockholder"forthreeyearsfollowingthedatethatsuchpersonbecameaninterestedstockholder,unlesseithertheinterestedstockholderattainedsuchstatuswiththeapprovalofourboardofdirectors,thebusinesscombinationisapprovedbyourboardofdirectorsandstockholdersinaprescribedmannerortheinterestedstockholderacquiredatleast85%ofouroutstandingvotingstockinthetransactioninwhichitbecameaninterestedstockholder.A"businesscombination"includes,amongotherthings,(i)amergerorconsolidationinvolvingusandthe"interestedstockholder"and(ii)thesaleofmorethan10%ofourassets.Ingeneral,an"interestedstockholder"isanyentityorpersonbeneficiallyowning15%ormoreofouroutstandingvotingstockandanyentityorpersonaffiliatedwithorcontrollingorcontrolledbysuchentityorperson.TherestrictionscontainedinSection203arenotapplicabletoanyofourexistingstockholdersthatowned15%ormoreofouroutstandingvotingstockupontheclosingofourinitialpublicoffering.
Staggered Board; Removal of Directors
Ourcertificateofincorporationandourby-lawsdivideourboardofdirectorsintothreeclasseswithstaggeredthree-yearterms.Inaddition,ourcertificateofincorporationandourby-lawsprovidethatdirectorsmayberemovedonlyforcauseandonlybytheaffirmativevoteoftheholdersof75%ofoursharesofcapitalstockpresentinpersonorbyproxyandentitledtovote.Underourcertificateofincorporationandby-laws,anyvacancyonourboardofdirectors,includingavacancyresultingfromanenlargementofourboardofdirectors,maybefilledonlybyvoteofamajorityofourdirectorstheninoffice.Furthermore,ourcertificateofincorporationprovidesthattheauthorizednumberofdirectorsmaybechangedonlybytheresolutionofourboardofdirectors.Theclassificationofourboardofdirectorsandthelimitationsontheabilityofourstockholderstoremovedirectors,changetheauthorizednumberofdirectorsandfillvacanciescouldmakeitmoredifficultforathirdpartytoacquire,ordiscourageathirdpartyfromseekingtoacquire,controlofourcompany.
11
![Page 17: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/17.jpg)
TableofContents
Stockholder Action; Special Meeting of Stockholders; Advance Notice Requirements for Stockholder Proposals and Director Nominations
Ourcertificateofincorporationandourby-lawsprovidethatanyactionrequiredorpermittedtobetakenbyourstockholdersatanannualmeetingorspecialmeetingofstockholdersmayonlybetakenifitisproperlybroughtbeforesuchmeetingandmaynotbetakenbywrittenactioninlieuofameeting.Ourcertificateofincorporationandourby-lawsalsoprovidethat,exceptasotherwiserequiredbylaw,specialmeetingsofthestockholderscanonlybecalledbythechairmanofourboardofdirectors,ourchiefexecutiveofficerorourboardofdirectors.Inaddition,ourby-lawsestablishanadvancenoticeprocedureforstockholderproposalstobebroughtbeforeanannualmeetingofstockholders,includingproposednominationsofcandidatesforelectiontoourboardofdirectors.Stockholdersatanannualmeetingmayonlyconsiderproposalsornominationsspecifiedinthenoticeofmeetingorbroughtbeforethemeetingbyoratthedirectionofourboardofdirectors,orbyastockholderofrecordontherecorddateforthemeetingwhoisentitledtovoteatthemeetingandwhohasdeliveredtimelywrittennoticeinproperformtooursecretaryofthestockholder'sintentiontobringsuchbusinessbeforethemeeting.Theseprovisionscouldhavetheeffectofdelayinguntilthenextstockholdermeetingstockholderactionsthatarefavoredbytheholdersofamajorityofouroutstandingvotingsecurities.Theseprovisionsalsocoulddiscourageathirdpartyfrommakingatenderofferforourcommonstockbecauseevenifthethirdpartyacquiredamajorityofouroutstandingvotingstock,itwouldbeabletotakeactionasastockholder,suchaselectingnewdirectorsorapprovingamerger,onlyatadulycalledstockholdersmeetingandnotbywrittenconsent.
Super-Majority Voting
TheDGCLprovidesgenerallythattheaffirmativevoteofamajorityofthesharesentitledtovoteonanymatterisrequiredtoamendacorporation'scertificateofincorporationorby-lawsunlessacorporation'scertificateofincorporationorby-laws,asthecasemaybe,requiresagreaterpercentage.Ourby-lawsmaybeamendedorrepealedbyamajorityvoteofourboardofdirectorsortheaffirmativevoteoftheholdersofatleast75%ofthevotesthatallourstockholderswouldbeentitledtocastinanyannualelectionofdirectors.Inaddition,theaffirmativevoteoftheholdersofatleast75%ofthevotesthatallourstockholderswouldbeentitledtocastinanyelectionofdirectorsisrequiredtoamendorrepealortoadoptanyprovisionsinconsistentwithanyoftheprovisionsofourcertificateofincorporationdescribedabove.
Registration Rights
Weenteredintoafourthamendedandrestatedinvestors'rightsagreementdatedJune30,2013,asamended,ortheinvestorrightsagreement,withholdersofourthen-outstandingpreferredstockpriortotheclosingofourinitialpublicoffering.Suchpreferredstockwasconvertedintocommonstockuponconsummationofourinitialpublicoffering.Holdersofatotalof2,656,538sharesofourcommonstockoutstandingorissuableuponexerciseofwarrantsoutstandingasofMarch15,2019havetherighttorequireustoregisterthesesharesundertheSecuritiesActunderspecifiedcircumstances.Afterregistrationpursuanttotheserights,theseshareswillbecomefreelytradablewithoutrestrictionundertheSecuritiesAct.Ifnototherwiseexercised,therightsundertheinvestorrightsagreementdescribedbelowwillexpirefiveyearsaftertheclosingofourinitialpublicoffering,whichoccurredonJuly30,2014.
Demand and Form S-3 Registration Rights
Subjecttospecifiedlimitationssetforthintheinvestorrightsagreement,atanytime,theholdersofatleast50%ofthethenoutstandingshareshavingrightsundertheinvestorrightsagreement,ortheregistrablesecurities,maydemandthatweregisterregistrablesecuritiesthenoutstandingundertheSecuritiesActforpurposesofapublicofferinghavinganaggregateofferingpricetothepublicofnot
12
![Page 18: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/18.jpg)
TableofContents
lessthan$10million.Wearenotobligatedtofilearegistrationstatementpursuanttothisprovisiononmorethantwooccasions.
Inaddition,subjecttospecifiedlimitationssetforthintheinvestorrightsagreement,atanytimeafterwebecomeeligibletofilearegistrationstatementonFormS-3,holdersoftheregistrablesecuritiesthenoutstandingmayrequestthatweregistertheirregistrablesecuritiesonFormS-3forpurposesofconductingapublicofferingforwhichthereasonablyanticipatedaggregateofferingpricetothepublicwouldexceed$1million.
Incidental Registration Rights
IfweproposetoregisterforourownaccountanyofoursecuritiesundertheSecuritiesAct,theholdersofregistrablesecuritieswillbeentitledtonoticeoftheregistrationand,subjecttospecifiedexceptions,havetherighttorequireustouseourbesteffortstoregisteralloraportionoftheregistrablesecuritiesthenheldbytheminthatregistration.Underouroutstandingwarrants,eachoftheholdersofthewarrantsisalsoentitledtonoticeoftheregistrationatthetimethatweprovidenoticeoftheregistrationtotheholdersofregistrablesecurities.Theholdersofregistrablesecuritieswaivedtheseincidentalregistrationrightsinconnectionwiththisoffering.
Intheeventthatanyregistrationinwhichtheholdersofregistrablesecuritiesparticipatepursuanttoourinvestorrightsagreementisanunderwrittenpublicofferingorifanywarrantholderparticipatesinsuchanofferingpursuanttothewarrants,wehaveagreedtoenterintoanunderwritingagreementcontainingcustomaryrepresentationsandwarrantiesandcovenants,includingwithoutlimitationcustomaryprovisionswithrespecttoindemnificationoftheunderwritersofsuchoffering.
Intheeventthatanyregistrationinwhichtheholdersofregistrablesecuritiesparticipatepursuanttoourinvestorrightsagreementisanunderwrittenofferingorifanywarrantholderparticipatespursuanttothewarrants,wewilluseourbesteffortstoincludetherequestedsecuritiestobeincluded,butsuchinclusionsmaybelimitedbymarketconditionstotheextentsetforthintheinvestorrightsagreement.
Expenses
Pursuanttotheinvestorrightsagreement,wearerequiredtopayallregistrationexpenses,includingallregistrationandfilingfees,exchangelistingfees,printingexpenses,feesandexpensesofonecounselselectedbythesellingstockholdersnamedthereintorepresentsuchsellingstockholders,stateBlueSkyfeesandexpenses,andtheexpenseofanyspecialauditsincidenttoorrequiredbyanysuchregistration,butexcludingunderwritingdiscounts,sellingcommissionsandthefeesandexpensesofthesellingstockholders'owncounsel(otherthanthecounselselectedtorepresentallsellingstockholders).Wearenotrequiredtopayregistrationexpensesiftheregistrationrequestundertheinvestorrightsagreementiswithdrawnattherequestofholdersinitiatingsuchregistrationrequest,unlessthewithdrawalisrelatedtoinformationconcerningthebusinessorfinancialconditionofusaftertheinitiationofsuchregistrationrequest.
Theinvestorrightsagreementcontainscustomarycross-indemnificationprovisions,pursuanttowhichweareobligatedtoindemnifythesellingstockholdersnamedthereinintheeventofmaterialmisstatementsoromissionsintheregistrationstatementattributabletousoranyviolationorallegedviolationwhetherbyactionorinactionbyusundertheSecuritiesAct,theExchangeAct,anystatesecuritiesorBlueSkylaworanyruleorregulationpromulgatedundertheSecuritiesAct,theExchangeActoranystatesecuritiesorBlueSkylawinconnectionwithsuchregistrationstatementorthequalificationorcomplianceoftheoffering,andtheyareobligatedtoindemnifyusformaterialmisstatementsoromissionsintheregistrationstatementattributabletothem.
Registration Rights Regarding Shares Issuable Upon Conversion of Convertible Notes
Asdescribedaboveundertheheading"SellingStockholders—DescriptionofTransactionswiththeSellingStockholders—Registration Rights Agreement ,"wealsoenteredintotheRegistrationRightsAgreementinconnectionwiththeissuanceandsaleoftheNotesontheClosingDate.
13
![Page 19: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/19.jpg)
TableofContents
PLANOFDISTRIBUTION
Thesellingstockholders,whichasusedhereinincludesdonees,pledgees,transfereesorothersuccessors-in-interestsellingsharesofcommonstockorinterestsinsharesofcommonstockreceivedafterthedateofthisprospectusfromasellingstockholderasagift,pledge,partnershipdistributionorothertransfer,may,fromtimetotime,sell,transferorotherwisedisposeofanyorallofitssharesofcommonstockorinterestsinsharesofcommonstockonanystockexchange,marketortradingfacilityonwhichthesharesaretradedorinprivatetransactions.Thesedispositionsmaybeatfixedprices,atprevailingmarketpricesatthetimeofsale,atpricesrelatedtotheprevailingmarketprice,atvaryingpricesdeterminedatthetimeofsale,oratnegotiatedprices.
Thesellingstockholdersmayuseanyoneormoreofthefollowingmethodswhendisposingofsharesorintereststherein:
• ordinarybrokeragetransactionsandtransactionsinwhichthebroker-dealersolicitspurchasers;
• blocktradesinwhichthebroker-dealerwillattempttosellthesharesasagent,butmaypositionandresellaportionoftheblockasprincipaltofacilitatethetransaction;
• purchasesbyabroker-dealerasprincipalandresalebythebroker-dealerforitsaccount;
• anexchangedistributioninaccordancewiththerulesoftheapplicableexchange;
• privatelynegotiatedtransactions;
• shortsaleseffectedafterthedatetheregistrationstatementofwhichthisprospectusisapartisdeclaredeffectivebytheSEC;
• throughthewritingorsettlementofoptionsorotherhedgingtransactions,whetherthroughanoptionsexchangeorotherwise;
• broker-dealersmayagreewithasellingstockholdertosellaspecifiednumberofsuchsharesatastipulatedpricepershare;
• acombinationofanysuchmethodsofsale;and
• anyothermethodpermittedbyapplicablelaw.
Totheextentrequired,thisprospectusmaybeamendedorsupplementedfromtimetotimetodescribeaspecificplanofdistribution.
Asellingstockholdermay,fromtimetotime,pledgeorgrantasecurityinterestinsomeorallofthesharesofcommonstockownedbyitand,ifitdefaultsintheperformanceofitssecuredobligations,thepledgeesorsecuredpartiesmayofferandsellthesharesofcommonstock,fromtimetotime,underthisprospectus,orunderanamendmenttothisprospectusunderRule424(b)(3)orotherapplicableprovisionoftheSecuritiesAct,amendingthelistofsellingstockholderstoincludethepledgee,transfereeorothersuccessorsininterestassellingstockholderunderthisprospectus.Asellingstockholderalsomaytransferthesharesofcommonstockinothercircumstances,inwhichcasethetransferees,pledgeesorothersuccessorsininterestwillbethesellingbeneficialownersforpurposesofthisprospectus.
Inconnectionwiththesaleofcommonstockorintereststherein,asellingstockholdermayenterintohedgingtransactionswithbroker-dealersorotherfinancialinstitutions,whichmayinturnengageinshortsalesofourcommonstockinthecourseofhedgingthepositionsitassumes.Asellingstockholdermayalsosellsharesofcommonstockshortanddeliverthesesecuritiestocloseoutitsshortpositions,orloanorpledgeourcommonstocktobroker-dealersthatinturnmaysellthesesecurities.Asellingstockholdermayalsoenterintooptionorothertransactionswithbroker-dealersorotherfinancialinstitutionsorthecreationofoneormorederivativesecuritieswhichrequirethe
14
![Page 20: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/20.jpg)
TableofContents
deliverytosuchbroker-dealerorotherfinancialinstitutionofsharesofferedbythisprospectus,whichsharessuchbroker-dealerorotherfinancialinstitutionmayresellpursuanttothisprospectus(assupplementedoramendedtoreflectsuchtransaction).
Theaggregateproceedstoasellingstockholderfromthesaleofourcommonstockofferedbyitwillbethepurchasepriceofthecommonstocklessdiscountsorcommissions,ifany.Thesellingstockholdersreservetherighttoacceptand,togetherwiththeiragentsfromtimetotime,toreject,inwholeorinpart,anyproposedpurchaseofourcommonstocktobemadedirectlyorthroughagents.Wewillnotreceiveanyoftheproceedsfromthisoffering.
AsellingstockholderalsomayresellalloraportionofthesharesinopenmarkettransactionsinrelianceuponRule144undertheSecuritiesAct,providedthattheymeetthecriteriaandconformtotherequirementsofthatrule.
Thesellingstockholdersandanyunderwriters,broker-dealersoragentsthatparticipateinthesaleofourcommonstockorintereststhereinmaybe"underwriters"withinthemeaningofSection2(11)oftheSecuritiesAct.Anydiscounts,commissions,concessionsorprofittheyearnonanyresaleofthesharesmaybeunderwritingdiscountsandcommissionsundertheSecuritiesAct.Asellingstockholderwhoisan"underwriter"withinthemeaningofSection2(11)oftheSecuritiesActwillbesubjecttotheprospectusdeliveryrequirementsoftheSecuritiesAct.
Totheextentrequired,thesharesofourcommonstocktobesold,thenameofthesellingstockholders,therespectivepurchasepricesandpublicofferingprices,thenamesofanyagents,dealerorunderwriter,andanyapplicablecommissionsordiscountswithrespecttoaparticularofferwillbesetforthinanaccompanyingprospectussupplementor,ifappropriate,apost-effectiveamendmenttotheRegistrationStatement.
Inordertocomplywiththesecuritieslawsofsomestates,ifapplicable,ourcommonstockmaybesoldinthosejurisdictionsonlythroughregisteredorlicensedbrokersordealers.Inaddition,insomestatessuchcommonstockmaynotbesoldunlessithasbeenregisteredorqualifiedforsaleoranexemptionfromregistrationorqualificationrequirementsisavailableandiscompliedwith.
Wehaveadvisedthesellingstockholdersthattheanti-manipulationrulesofRegulationMpromulgatedundertheExchangeActmayapplytosalesofsharesinthemarketandtotheactivitiesofthesellingstockholdersandtheiraffiliates.Inaddition,totheextentapplicablewewillmakecopiesofthisprospectus(asitmaybesupplementedoramendedfromtimetotime)availabletothesellingstockholdersforthepurposeofsatisfyingtheprospectusdeliveryrequirementsoftheSecuritiesAct.Thesellingstockholdersmayindemnifyanybroker-dealerthatparticipatesintransactionsinvolvingthesaleofthesharesagainstcertainliabilities,includingliabilitiesarisingundertheSecuritiesAct.
Wehaveagreedtoindemnifythesellingstockholdersagainstliabilities,includingliabilitiesundertheSecuritiesActandstatesecuritieslaws,relatingtotheregistrationofthesharesofferedbythisprospectus.
WehaveagreedwiththesellingstockholderstokeeptheRegistrationStatementeffectiveuntiltheearlierof(1)suchtimeasallofthesharescoveredbythisprospectusandactuallyissuedorissuableuponconversionoftheNoteshavebeensoldand(2)thedateonwhichallofthesharesmaybesoldwithoutrestrictionpursuanttoRule144oftheSecuritiesAct.
15
![Page 21: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/21.jpg)
TableofContents
LEGALMATTERS
ThevalidityofthesharesofourcommonstockbeingofferedbythisprospectushasbeenpasseduponforusbyWilmerCutlerPickeringHaleandDorrLLP.
EXPERTS
ThefinancialstatementsincorporatedinthisProspectusbyreferencetotheAnnualReportonForm10-KfortheyearendedDecember31,2018havebeensoincorporatedinrelianceonthereport(whichcontainsanexplanatoryparagraphrelatingtotheCompany'sabilitytocontinueasagoingconcernasdescribedinNote1tothefinancialstatements)ofPricewaterhouseCoopersLLP,anindependentregisteredpublicaccountingfirm,givenontheauthorityofsaidfirmasexpertsinauditingandaccounting.
WHEREYOUCANFINDMOREINFORMATION
Wefileannual,quarterlyandcurrentreports,proxystatementsandotherinformationwiththeSEC.OurSECfilingsareavailabletothepublicovertheInternetattheSEC'swebsiteathttp://www.sec.gov.CopiesofcertaininformationfiledbyuswiththeSECarealsoavailableonourwebsiteathttp://www.ocutx.com.Ourwebsiteisnotapartofthisprospectusandisnotincorporatedbyreferenceinthisprospectus.
ThisprospectusconstitutesapartofaregistrationstatementonFormS-3thatwehavefiledwiththeSECundertheSecuritiesAct.Theregistrationstatementcontainsmoreinformationthanthisprospectusregardingusandourcommonstock,includingcertainexhibitsandschedules.YoucanobtainacopyoftheregistrationstatementfromtheSEC'sInternetsiteorourwebsite.
INCORPORATIONOFCERTAINDOCUMENTSBYREFERENCE
TheSECrequiresusto"incorporate"intothisprospectusinformationthatwefilewiththeSECinotherdocuments.Thismeansthatwecandiscloseimportantinformationtoyoubyreferringtootherdocumentsthatcontainthatinformation.Theinformationincorporatedbyreferenceisconsideredtobepartofthisprospectus.InformationcontainedinthisprospectusandinformationthatwefilewiththeSECinthefutureandincorporatebyreferenceinthisprospectusautomaticallyupdatesandsupersedespreviouslyfiledinformation.WeincorporatebyreferencethedocumentslistedbelowandanyfuturefilingswemakewiththeSECunderSections13(a),13(c),14or15(d)oftheExchangeActafterthedateofthisprospectusandpriortothesaleofallthesharescoveredbythisprospectus.
(1) OurAnnualReportonForm10-KfortheyearendedDecember31,2018;
(2) TheinformationincludedinourdefinitiveproxystatementonSchedule14Aforthe2018AnnualMeetingofStockholders,filedonApril23,2018,totheextentincorporatedbyreferenceintoPartIIIoftheAnnualReportonForm10-KforthefiscalyearendedDecember31,2017;
(3) OurCurrentReportsonForm8-KdatedFebruary20,2019;February22,2019;andMarch25,2019;
(4) AnyotherfilingswemakepursuanttotheExchangeActafterthedateoffilingtheinitialregistrationstatementandpriortoeffectivenessoftheregistrationstatement;and
(5) ThedescriptionofourcommonstockcontainedinourRegistrationStatementonForm8-AfiledonJuly21,2014,includinganyamendmentsorreportsfiledforthepurposeofupdatingsuchdescription.
16
![Page 22: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/22.jpg)
TableofContents
Astatementcontainedinadocumentincorporatedbyreferenceintothisprospectusshallbedeemedtobemodifiedorsupercededforpurposesofthisprospectustotheextentthatastatementcontainedinthisprospectusorinanyothersubsequentlyfileddocumentwhichisalsoincorporatedinthisprospectusmodifiesorreplacessuchstatement.Anystatementssomodifiedorsupercededshallnotbedeemed,exceptassomodifiedorsuperceded,toconstituteapartofthisprospectus.
Youmayrequestacopyofthesedocuments,whichwillbeprovidedtoyouatnocost,bywritingortelephoningususingthefollowingcontactinformation:
OcularTherapeutix,Inc.Attn:ChiefFinancialOfficer
15CrosbyDriveBedford,MA01730(781)357-4000
17
![Page 23: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/23.jpg)
TableofContents
PROSPECTUS
9,574,020SHARESOFCOMMONSTOCK
,2019
![Page 24: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/24.jpg)
TableofContents
PARTII
INFORMATIONNOTREQUIREDINPROSPECTUS
Item14.OtherExpensesofIssuanceandDistribution.
Thefollowingtablesetsforththevariousexpensestobeincurredinconnectionwiththesaleanddistributionofourcommonstockbeingregisteredhereby,allofwhichwillbebornebyOcularTherapeutix,Inc.(exceptanyunderwritingdiscountsandcommissionsandexpensesincurredbythesellingstockholdersforbrokerage,accounting,taxorlegalservicesoranyotherexpensesincurredbythesellingstockholdersindisposingoftheshares).AllamountsshownareestimatesexcepttheSECregistrationfee.
Item15.IndemnificationofDirectorsandOfficers.
Section102oftheDGCLpermitsacorporationtoeliminatethepersonalliabilityofitsdirectorsoritsstockholdersformonetarydamagesforabreachoffiduciarydutyasadirector,exceptwherethedirectorbreachedhisorherdutyofloyalty,failedtoactingoodfaith,engagedinintentionalmisconductorknowinglyviolatedalaw,authorizedthepaymentofadividendorapprovedastockrepurchaseinviolationofDelawarecorporatelaworobtainedanimproperpersonalbenefit.Ourcertificateofincorporationprovidesthatnodirectorshallbepersonallyliabletousorourstockholdersformonetarydamagesforanybreachoffiduciarydutyasadirector,notwithstandinganyprovisionoflawimposingsuchliability,excepttotheextentthattheDGCLprohibitstheeliminationorlimitationofliabilityofdirectorsforbreachesoffiduciaryduty.
Section145oftheDGCLprovidesthatacorporationhasthepowertoindemnifyadirector,officer,employeeoragentofthecorporationandcertainotherpersonsservingattherequestofthecorporationinrelatedcapacitiesagainstexpenses(includingattorneys'fees),judgments,finesandamountspaidinsettlementsactuallyandreasonablyincurredbythepersoninconnectionwithanaction,suitorproceedingtowhichheorsheisoristhreatenedtobemadeapartybyreasonofsuchposition,ifsuchpersonactedingoodfaithandinamannerheorshereasonablybelievedtobeinornotopposedtothebestinterestsofthecorporation,and,inanycriminalactionorproceeding,hadnoreasonablecausetobelievehisorherconductwasunlawful,exceptthat,inthecaseofactionsbroughtbyorintherightofthecorporation,noindemnificationshallbemadewithrespecttoanyclaim,issueormatterastowhichsuchpersonshallhavebeenadjudgedtobeliabletothecorporationunlessandonlytotheextentthattheCourtofChanceryorotheradjudicatingcourtdeterminesthat,despitetheadjudicationofliabilitybutinviewofallofthecircumstancesofthecase,suchpersonisfairlyandreasonablyentitledtoindemnificationforsuchexpenseswhichtheCourtofChanceryorsuchothercourtshalldeemproper.
Ourcertificateofincorporationprovidesthatwewillindemnifyeachpersonwhowasorisapartyorthreatenedtobemadeapartytoanythreatened,pendingorcompletedaction,suitorproceeding,whethercivil,criminal,administrativeorinvestigative(otherthananactionbyorintherightofus),byreasonofthefactthatheorsheisorwas,orhasagreedtobecome,ourdirectororofficer,orisorwasserving,orhasagreedtoserve,atourrequestasadirector,officer,partner,employeeortrusteeof,orinasimilarcapacitywith,anothercorporation,partnership,jointventure,trustorotherenterprise(allsuchpersonsbeingreferredtoasanIndemnitee),orbyreasonofanyactionallegedtohavebeentakenoromittedinsuchcapacity,againstallexpenses(includingattorneys'fees),judgments,finesandamountspaidinsettlementactuallyandreasonablyincurredinconnectionwithsuchaction,suitorproceedingandanyappealtherefromifsuchIndemniteeactedingoodfaithandinamanner
SECregistrationfee $ 4,572Legalfeesandexpenses $ 50,000Accountingfeesandexpenses $ 40,000Miscellaneousexpenses $ 5,428Totalexpenses $ 100,000
![Page 25: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/25.jpg)
TableofContents
heorshereasonablybelievedtobein,ornotopposedto,ourbestinterests,and,withrespecttoanycriminalactionorproceeding,heorshehadnoreasonablecausetobelievehisorherconductwasunlawful.
OurcertificateofincorporationalsoprovidesthatwewillindemnifyanyIndemniteewhowasorisapartytoanactionorsuitbyorintherightofustoprocureajudgmentinourfavorbyreasonofthefactthattheIndemniteeisorwas,orhasagreedtobecome,ourdirectororofficer,orisorwasserving,orhasagreedtoserve,atourrequestasadirector,officer,partner,employeeortrusteeor,orinasimilarcapacitywith,anothercorporation,partnership,jointventure,trustorotherenterprise,orbyreasonofanyactionallegedtohavebeentakenoromittedinsuchcapacity,againstallexpenses(includingattorneys'fees)and,totheextentpermittedbylaw,amountspaidinsettlementactuallyandreasonablyincurredinconnectionwithsuchaction,suitorproceeding,andanyappealtherefrom,iftheIndemniteeactedingoodfaithandinamannerheorshereasonablybelievedtobein,ornotopposedto,ourbestinterests,exceptthatnoindemnificationshallbemadewithrespecttoanyclaim,issueormatterastowhichsuchpersonshallhavebeenadjudgedtobeliabletous,unlessacourtdeterminesthat,despitesuchadjudicationbutinviewofallofthecircumstances,heorsheisentitledtoindemnificationofsuchexpenses.Notwithstandingtheforegoing,totheextentthatanyIndemniteehasbeensuccessful,onthemeritsorotherwise,heorshewillbeindemnifiedbyusagainstallexpenses(includingattorneys'fees)actuallyandreasonablyincurredbyhimorheroronhisorherbehalfinconnectiontherewith.Ifwedonotassumethedefense,expensesmustbeadvancedtoanIndemniteeundercertaincircumstances.
Wehaveenteredintoindemnificationagreementswithallofourdirectorsandexecutiveofficers.Ingeneral,theseagreementsprovidethatwewillindemnifythedirectororofficertothefullestextentpermittedbylawforclaimsarisinginhisorhercapacityasadirectororofficerofourcompanyorinconnectionwiththeirserviceatourrequestforanothercorporationorentity.Theindemnificationagreementsalsoprovideforproceduresthatwillapplyintheeventthatadirectororofficermakesaclaimforindemnificationandestablishcertainpresumptionsthatarefavorabletothedirectororofficer.
Wemaintainageneralliabilityinsurancepolicythatcoverscertainliabilitiesofourdirectorsandofficersarisingoutofclaimsbasedonactsoromissionsintheircapacitiesasdirectorsorofficers.
Inanyunderwritingagreementweenterintoinconnectionwiththeofferingofcommonstockbeingregisteredhereby,theunderwriterswillagreetoindemnify,undercertainconditions,ourdirectorsandofficers(aswellascertainotherpersons)againstcertainliabilitiesarisinginconnectionwithsuchoffering.
Insofarastheforgoingprovisionspermitindemnificationofdirectors,executiveofficers,orpersonscontrollingusforliabilityarisingundertheSecuritiesActwehavebeeninformedthat,intheopinionoftheSEC,suchindemnificationisagainstpublicpolicyasexpressedintheSecuritiesActandisthereforeunenforceable.
Item16.Exhibits
ExhibitNumber Description 4.1 RestatedCertificateofIncorporationoftheRegistrant(incorporatedbyreferencetoExhibit3.1toourCurrentReport
onForm8-K(FileNo.001-36554)filedwiththeSEConJuly30,2014)
4.2 AmendedandRestatedBy-lawsoftheRegistrant(incorporatedbyreferencetoExhibit3.2toourCurrentReportonForm8-K(FileNo.001-36554)filedwiththeSEConJuly30,2014)
4.3 SpecimenStockCertificateevidencingthesharesofcommonstock(incorporatedbyreferencetoExhibit4.1toourRegistrationStatementonFormS-1/A(FileNo.333-196932)filedwiththeSEConJuly11,2014)
![Page 26: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/26.jpg)
TableofContents
Item17.Undertakings.
Item 512(a) of Regulation S-K. TheundersignedRegistrantherebyundertakes:
(1)Tofile,duringanyperiodinwhichoffersorsalesarebeingmade,apost-effectiveamendmenttothisRegistrationStatement:
(i)ToincludeanyprospectusrequiredbySection10(a)(3)oftheSecuritiesActof1933,asamended(the"SecuritiesAct");
(ii)ToreflectintheprospectusanyfactsoreventsarisingaftertheeffectivedateofthisRegistrationStatement(orthemostrecentpost-effectiveamendmentthereof)which,individuallyorintheaggregate,representafundamentalchangeintheinformationsetforthinthisRegistrationStatement.Notwithstandingtheforegoing,anyincreaseordecreaseinthevolumeofsecuritiesoffered(ifthetotaldollarvalueofsecuritiesofferedwouldnotexceedthatwhichwasregistered)andanydeviationfromtheloworhighendoftheestimatedmaximumofferingrangemaybereflectedintheformofprospectusfiledwiththeCommissionpursuanttoRule424(b)if,intheaggregate,thechangesinvolumeandpricerepresentnomorethan20percentchangeinthemaximumaggregateofferingpricesetforthinthe"CalculationofRegistrationFee"tableintheeffectiveRegistrationStatement;and
(iii)ToincludeanymaterialinformationwithrespecttotheplanofdistributionnotpreviouslydisclosedinthisRegistrationStatementoranymaterialchangetosuchinformationinthisRegistrationStatement;
provided, however ,thatparagraphs(1)(i),(1)(ii)and(1)(iii)abovedonotapplyiftheinformationrequiredtobeincludedinapost-effectiveamendmentbythoseparagraphsiscontainedinreportsfiledwithorfurnishedtotheCommissionbytheRegistrantpursuanttoSection13orSection15(d)oftheSecuritiesExchangeActof1934,asamended(the"ExchangeAct"),thatare
ExhibitNumber Description 4.4 FourthAmendedandRestatedInvestors'RightsAgreementoftheRegistrant(incorporatedbyreferencetoExhibit4.2
toourRegistrationStatementonFormS-1(FileNo.333-196932)filedwiththeSEConJune20,2014)
4.5 NotePurchaseAgreement(includingFormofSeniorSubordinatedConvertibleNote),datedasofFebruary21,2019,byandamongtheRegistrantandthePurchaserslistedtherein(incorporatedbyreferencetoExhibit10.1toourCurrentReportonForm8-K(FileNo.001-36554)filedwiththeSEConFebruary22,2019)
4.6 SeniorSubordinatedConvertibleNote,datedMarch1,2019,byandbetweentheRegistrantandCap1LLC
4.7 RegistrationRightsAgreement,datedMarch1,2019,byandamongtheRegistrantandthePurchaserslistedtherein(incorporatedbyreferencetoExhibit4.2toourAnnualReportonForm10-K(FileNo.001-36554)filedwiththeSEConMarch7,2019)
4.8 SubordinationAgreement,datedasofFebruary21,2019,byandamongtheRegistrant,MidCapFinancialTrust,asadministrativeagent,andtheLenderslistedtherein(incorporatedbyreferencetoExhibit10.4toourCurrentReportonForm8-K(FileNo.001-36554)filedwiththeSEConFebruary22,2019)
5.1 OpinionofWilmerCutlerPickeringHaleandDorrLLP
23.1 ConsentofPricewaterhouseCoopersLLP,anindependentregisteredpublicaccountingfirm
23.2 ConsentofWilmerHale(includedinExhibit5.1)
24.1 PowerofAttorney(includedinthesignaturepagestotheRegistrationStatement)
![Page 27: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/27.jpg)
TableofContents
incorporatedbyreferenceinthisRegistrationStatementoriscontainedinaformofprospectusfiledpursuanttoRule424(b)thatispartofthisRegistrationStatement.
(2)That,forthepurposesofdetermininganyliabilityundertheSecuritiesAct,eachsuchpost-effectiveamendmentshallbedeemedtobeanewregistrationstatementrelatingtothesecuritiesofferedtherein,andtheofferingofsuchsecuritiesatthetimeshallbedeemedtobetheinitialbona fideofferingthereof.
(3)Toremovefromregistrationbymeansofapost-effectiveamendmentanyofthesecuritiesbeingregisteredwhichremainunsoldattheterminationoftheoffering.
(4)That,forthepurposeofdeterminingliabilityundertheSecuritiesActtoanypurchaser:
(i)EachprospectusfiledbytheRegistrantpursuanttoRule424(b)(3)shallbedeemedtobepartofthisRegistrationStatementasofthedatethefiledprospectuswasdeemedpartofandincludedintheRegistrationStatement;and
(ii)EachprospectusrequiredtobefiledpursuanttoRule424(b)(2),(b)(5),or(b)(7)aspartofaregistrationstatementinrelianceonRule430BrelatingtoanofferingmadepursuanttoRule415(a)(1)(i),(vii),or(x)forthepurposeofprovidingtheinformationrequiredbySection10(a)oftheSecuritiesActshallbedeemedtobepartofandincludedinthisRegistrationStatementasoftheearlierofthedatesuchformofprospectusisfirstusedaftereffectivenessorthedateofthefirstcontractofsaleofsecuritiesintheofferingdescribedintheprospectus.AsprovidedinRule430B,forliabilitypurposesoftheissuerandanypersonthatisatthatdateanunderwriter,suchdateshallbedeemedtobeaneweffectivedateoftheregistrationstatementrelatingtothesecuritiesintheregistrationstatementtowhichthatprospectusrelates,andtheofferingofsuchsecuritiesatthattimeshallbedeemedtobetheinitialbona fide offeringthereof.Provided ,however ,thatnostatementmadeinaregistrationstatementorprospectusthatispartoftheregistrationstatementormadeinadocumentincorporatedordeemedincorporatedbyreferenceintotheregistrationstatementorprospectusthatispartoftheregistrationstatementwill,astoapurchaserwithatimeofcontractofsalepriortosucheffectivedate,supersedeormodifyanystatementthatwasmadeintheregistrationstatementorprospectusthatwaspartoftheregistrationstatementormadeinanysuchdocumentimmediatelypriortosucheffectivedate.
Item 512(b) of Regulation S-K. TheundersignedRegistrantherebyundertakesthat,forpurposesofdetermininganyliabilityundertheSecuritiesAct,eachfilingoftheRegistrant'sannualreportpursuanttoSection13(a)or15(d)oftheExchangeAct(and,whereapplicable,eachfilingofanemployeebenefitplan'sannualreportpursuanttoSection15(d)oftheExchangeAct)thatisincorporatedbyreferenceinthisRegistrationStatementshallbedeemedtobeanewregistrationstatementrelatingtothesecuritiesofferedtherein,andtheofferingofsuchsecuritiesatthattimeshallbedeemedtobetheinitialbona fide offeringthereof.
Item 512(h) of Regulation S-K. InsofarasindemnificationforliabilitiesarisingundertheSecuritiesActmaybepermittedtodirectors,officersandcontrollingpersonsoftheRegistrantpursuanttotheindemnificationprovisionsdescribedherein,orotherwise,theRegistranthasbeenadvisedthatintheopinionoftheSecuritiesandExchangeCommissionsuchindemnificationisagainstpublicpolicyasexpressedintheSecuritiesActandis,therefore,unenforceable.Intheeventthataclaimforindemnificationagainstsuchliabilities(otherthanthepaymentbytheRegistrantofexpensesincurredorpaidbyadirector,officerorcontrollingpersonoftheRegistrantinthesuccessfuldefenseofanyaction,suitorproceeding)isassertedbysuchdirector,officerorcontrollingpersoninconnectionwiththesecuritiesbeingregistered,theRegistrantwill,unlessintheopinionofitscounselthematterhasbeensettledbycontrollingprecedent,submittoacourtofappropriatejurisdictionthequestionwhethersuchindemnificationbyitisagainstpublicpolicyasexpressedintheSecuritiesActandwillbegovernedbythefinaladjudicationofsuchissue.
![Page 28: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/28.jpg)
TableofContents
SIGNATURES
PursuanttotherequirementsoftheSecuritiesActof1933,asamended,theRegistrantcertifiesthatithasreasonablegroundstobelievethatitmeetsalloftherequirementsforfilingonFormS-3andhasdulycausedthisRegistrationStatementtobesignedonitsbehalfbytheundersigned,thereuntodulyauthorized,intheCityofBedford,CommonwealthofMassachusetts,onApril1,2019.
SIGNATURESANDPOWEROFATTORNEY
We,theundersignedofficersanddirectorsofOcularTherapeutix,Inc.,herebyseverallyconstituteandappointAntonyMattessichandDonaldNotman,andeachofthemsingly,ourtrueandlawfulattorneyswithfullpowertoanyofthem,andtoeachofthemsingly,tosignforusandinournamesinthecapacitiesindicatedbelowtheRegistrationStatementonFormS-3filedherewithandanyandallpre-effectiveandpost-effectiveamendmentstosaidRegistrationStatementandgenerallytodoallsuchthingsinournameandbehalfinourcapacitiesasofficersanddirectorstoenableOcularTherapeutix,Inc.tocomplywiththeprovisionsoftheSecuritiesActof1933,asamended,andallrequirementsoftheSecuritiesandExchangeCommission,herebyratifyingandconfirmingoursignaturesastheymaybesignedbyoursaidattorneys,oranyofthem,tosaidRegistrationStatementandanyandallamendmentsthereto.
PursuanttotherequirementsoftheSecuritiesActof1933,asamended,thisRegistrationStatementhasbeensignedbythefollowingpersonsinthecapacitiesandonthedatesindicated.
OCULARTHERAPEUTIX,INC.
By:/s/AntonyMattessich
Name: AntonyMattessich Title: President and Chief Executive Officer
Signature Title Date
/s/AntonyMattessich
AntonyMattessich
PresidentandChiefExecutiveOfficerandDirector(PrincipalExecutiveOfficer) April1,2019
/s/DonaldNotman
DonaldNotman
ChiefFinancialOfficer(PrincipalFinancialandAccountingOfficer)
April1,2019
/s/AmarpreetSawhney,Ph.D.
AmarpreetSawhney,Ph.D.
ChairmanoftheBoard April1,2019
/s/JaswinderChadha
JaswinderChadha
Director April1,2019
/s/JeffreyS.Heier,M.D.
JeffreyS.Heier,M.D.
Director April1,2019
![Page 29: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/29.jpg)
TableofContents
Signature Title Date
/s/RichardL.Lindstrom,M.D.
RichardL.Lindstrom,M.D.
Director April1,2019
/s/WilliamJamesO'Shea
WilliamJamesO'Shea
Director April1,2019
/s/BruceA.Peacock
BruceA.Peacock
Director April1,2019
/s/CharlesWarden
CharlesWarden
Director April1,2019
/s/LeslieJ.Williams
LeslieJ.Williams
Director April1,2019
![Page 30: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/30.jpg)
![Page 31: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/31.jpg)
Exhibit 4.6THISSECURITYANDTHECOMMONSTOCKISSUABLEUPONCONVERSIONOFTHISSECURITYHAVENOTBEENREGISTEREDUNDERTHESECURITIESACTOF1933,ASAMENDED(THE“SECURITIESACT”),ORAPPLICABLESTATESECURITIESLAWS.THESECURITIESMAYNOTBESOLD,TRANSFERREDORASSIGNEDINTHEABSENCEOFANEFFECTIVEREGISTRATIONSTATEMENTFORTHESECURITIESUNDERTHESECURITIESACT,ORPURSUANTTOANEXEMPTIONFROMREGISTRATIONUNDERTHESECURITIESACT.INTHECASEOFATRANSACTIONEXEMPTFROMREGISTRATIONTHECOMPANYRESERVESTHERIGHTTOREQUIREANOPINIONOFCOUNSELSATISFACTORYTOITASTOTHEAVAILABILITYOFANYEXEMPTIONFROMTHEREGISTRATIONREQUIREMENTSOFTHESECURITIESACT.THISNOTEANDTHEINDEBTEDNESS,RIGHTSANDOBLIGATIONSEVIDENCEDHEREBYARESUBORDINATEINTHEMANNERANDTOTHEEXTENTSETFORTHINTHATCERTAINSUBORDINATIONAGREEMENT(ASAMENDED,RESTATED,SUPPLEMENTEDOROTHERWISEMODIFIED,THE“SUBORDINATIONAGREEMENT”)DATEDASOFFEBRUARY21,2019,AMONGTHECOMPANY(ASDEFINEDBELOW),CAP1LLC,ASAGENTFORHOLDERANDALLOTHERHOLDERS(ASDEFINEDINTHENOTEPURCHASEAGREEMENT(ASDEFINEDBELOW)),ANDMIDCAPFINANCIALTRUST,ASADMINISTRATIVEAGENTFORTHELENDERS(ASDEFINEDINTHESUBORDINATIONAGREEMENT);ANDTHEHOLDEROFTHISNOTE,ANDEACHFUTUREHOLDEROFTHISNOTE,BYITSACCEPTANCEHEREOF,SHALLBEBOUNDBYTHEPROVISIONSOFTHESUBORDINATIONAGREEMENT.
![Page 32: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/32.jpg)
SENIOR SUBORDINATED CONVERTIBLE NOTE
IssuanceDate:March1,2019 Principal:U.S.$37,500,000FOR VALUE RECEIVED, OCULAR THERAPEUTIX, INC .,aDelawarecorporation(the“Company ”),herebypromisestopaytoCAP1LLC,oritsregisteredassigns(the“Holder ”)theprincipalamountofTHIRTY SEVEN MILLION FIVE HUNDRED THOUSAND DOLLARS ($37,500,000) pursuantto,andinaccordancewith,thetermsofthatcertainNotePurchaseAgreement,datedasofFebruary21,2019,byandamongtheCompanyandthePurchaserssetforthonSchedule1thereto(togetherwithallexhibitsandschedulestheretoandasmaybeamended,restated,modifiedandsupplementedfromtimetotime,the“Note Purchase Agreement ”).TheCompanyherebypromisestopayaccruedandunpaidInterest(asdefinedbelow)assetforthbelow.ThisSeniorSubordinatedConvertibleNote(includingallSeniorSubordinatedConvertibleNotesissuedinexchange,transferorreplacementhereof,andasanyoftheforegoingmaybeamended,restated,supplementedorotherwisemodifiedfromtimetotime,this“Note ”)isoneoftheSeniorSubordinatedConvertibleNotesissuedpursuanttotheNotePurchaseAgreement(collectively,includingallSeniorSubordinatedConvertibleNotesissuedinexchange,transferorreplacementthereof,andasanyoftheforegoingmaybeamended,restated,supplementedorotherwisemodifiedfromtimetotime,the“Notes ”).AllcapitalizedtermsusedandnototherwisedefinedhereinshallhavetherespectivemeaningssetforthintheNotePurchaseAgreement.
1.Definitions.
(a)CertainDefinedTerms.ForpurposesofthisNote,thefollowingtermsshallhavethefollowingmeanings:
(i)“Affiliate ”meansanypersonorentitythat,directlyorindirectlythroughoneormoreintermediaries,controlsoriscontrolledbyorisundercommoncontrolwithapersonorentity,assuchtermsareusedinandconstruedunderRule144undertheSecuritiesAct.WithrespecttoaHolder,anyinvestmentfundormanagedaccountthatismanagedonadiscretionarybasisbythesameinvestmentmanagerassuchHolderwillbedeemedtobeanAffiliateofsuchHolder.Asusedinthisdefinitionof“Affiliate,”theterm“control”meansthepossession,directlyorindirectly,ofthepowertodirectorcausethedirectionofthemanagementandpoliciesofaPerson,whetherthroughownershipofvotingsecuritiesorpartnershiporotherownershipinterest,bycontract,orotherwise.
(ii)“Business Day ”meansanydayotherthanaSaturday,aSundayoradayonwhichtheFederalReserveBankofNewYorkisauthorizedorrequiredbylaw,regulationorexecutiveordertocloseorbeclosed.
(iii)“Cash Settlement ”shallhavethemeaningsetforthinSection4(e)(i).
(iv)“Combination Settlement ”shallhavethemeaningsetforthinSection4(e)(i).
1
![Page 33: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/33.jpg)
(v)“Common Stock ”meansthecommonstock,parvalue$0.0001pershare,oftheCompany.
(vi)“Conversion Amount ”meansthePrincipaltobeconverted,redeemedorotherwisewithrespecttowhichthisdetermination
isbeingmade.
(vii)“Conversion Date ”meansanyofaCorporateTransactionConversionDateoraHolderConversionDate.
(viii)“Conversion Notice ”shallhavethemeaningsetforthinSection4(a).
(ix)“Conversion Price ”means,asofanydate,$1,000,dividedbytheConversionRateasofsuchdate.
(x)“Conversion Rate ”means,initially153.8462Sharesper$1,000principalamountoftheNotes,subjecttoadjustment,andtothesettlementprovisions,asprovidedinthisNote.
(xi)“Conversion Shares ”meanstheSharesissuedorissuableupontheconversionoftheNote.
(xii)“Corporate Transaction ”meansanyofthefollowingeventsoccurringpriortoorontheMaturityDate:(1)exceptasdescribedinclause(2)below,a“person”or“group”withinthemeaningofSection13(d)oftheExchangeAct,otherthantheCompanyoritsSubsidiaries,filesaScheduleTO(oranysuccessorschedule,formorreport)oranyschedule,formorreportundertheExchangeActdisclosingthatsuchpersonorgrouphasbecomethedirectorindirect“beneficialowner,”asdefinedinRule13d-3undertheExchangeAct,ofCommonStockrepresentingmorethan50%ofthevotingpoweroftheCommonStock;(2)theconsummationof(A)anyrecapitalization,reclassificationorchangeoftheCommonStock(otherthanchangesresultingfromasubdivisionorcombinationorsolelyachangeinparvalue)asaresultofwhichtheCommonStockwouldbeconvertedinto,orexchangedfor,stock,othersecurities,otherpropertyorassets(otherthanatransactiondescribedinclause(B)below),(B)anyshareexchange,consolidationormergeroftheCompanypursuanttowhichtheCommonStockwillbeconvertedintocash,securitiesorotherpropertyorassets,or(C)anysale,leaseorothertransferinonetransactionoraseriesoftransactionsofallorsubstantiallyalloftheconsolidatedassetsoftheCompanyanditsSubsidiaries,takenasawhole,toanypersonotherthanoneoftheCompany’sdirectorindirectwholly-ownedsubsidiaries;provided,however,thatneither(i)atransactiondescribedinclause(A)or(B)inwhichtheholdersofallclassesoftheCompany’scapitalstockimmediatelypriortosuchtransactionown,directlyorindirectly,morethan50%ofallclassesofthecapitalstockofthecontinuingorsurvivingcorporationortransfereeortheparentthereofimmediatelyaftersuchtransactioninsubstantiallythesameproportions(relativetoeachother)assuchownershipimmediatelypriortosuchtransactionnor(ii)anymergerorconsolidationoftheCompanysolelyforthepurposeofchangingitsjurisdictionofincorporationthatresultsinareclassification,conversionorexchangeofoutstandingsharesofCommonStocksolelyintosharesofcommonstockofthesurvivingentityshallbedeemedaCorporateTransaction;or(3)theCommonStockceasestobelistedorquoted
2
![Page 34: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/34.jpg)
onanyofTheNewYorkStockExchange,TheNasdaqGlobalSelectMarket,TheNasdaqGlobalMarketortheNasdaqCapitalMarket(oranyoftheirrespectivesuccessors).Atransactionortransactionsdescribedinclause(2)aboveshallnotconstituteaCorporateTransactionifatleast90%oftheconsiderationreceivedortobereceivedbytheholdersofCommonStock,excludingcashpaymentsforfractionalsharesandcashpaymentsmadeinrespectofdissenters’appraisalrights,inconnectionwithsuchtransactionortransactionsconsistsofsharesofcommonstockthatarelistedorquotedonanyofTheNewYorkStockExchange,TheNasdaqGlobalSelectMarketorTheNasdaqGlobalMarket(oranyoftheirrespectivesuccessors)orwillbesolistedorquotedwhenissuedorexchangedinconnectionwithsuchtransactionortransactionsandasaresultofsuchtransactionortransactionstheNotesbecomeconvertibleintosuchconsideration,excludingcashpaymentsforfractionalsharesandcashpaymentsmadeinrespectofdissenters’appraisalrights.
(xiii)“Corporate Transaction Conversion Date ”meansthedateofdeliveryofaCorporateTransactionConversionNoticepursuanttoSection4(b).
(xiv)“Corporate Transaction Conversion Notice ”shallhavethemeaningsetforthinSection4(b).
(xv)“Corporate Transaction Notice ”meansanoticespecifyingthataCorporateTransactionhasoccurred,thematerialtermsandconditionsoftheCorporateTransactionandspecifyingtheRepurchaseDate.
(xvi)“Corporate Transaction Repurchase Date ”shallhavethemeaningsetforthinSection13.
(xvii)“Corporate Transaction Repurchase Notice ”shallhavethemeaningsetforthinSection13.
(xviii)“Corporate Transaction Repurchase Option ”shallhavethemeaningsetforthinSection13.
(xix)“Daily Conversion Value ”means,foreachofthe20consecutiveTradingDaysduringtheObservationPeriod,5.0%oftheproductof(a)theConversionRateonsuchTradingDayand(b)theDailyVWAPonsuchTradingDay.
(xx)“Daily Measurement Value ”meanstheSpecifiedDollarAmount,ifany,dividedby20.
(xxi)“Daily Settlement Amount ,”foreachofthe20consecutiveTradingDaysduringtheObservationPeriod,shallconsistof:
(a)cashinanamountequaltothelesserof(i)theDailyMeasurementValueand(ii)theDailyConversionValueonsuchTradingDay;and
(b)iftheDailyConversionValueonsuchTradingDayexceedstheDailyMeasurementValue,anumberofSharesequalto(i)the
3
![Page 35: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/35.jpg)
differencebetweentheDailyConversionValueandtheDailyMeasurementValue,dividedby(ii)theDailyVWAPforsuchTradingDay.
(xxii)“Daily VWAP ”means,foreachofthe20consecutiveTradingDaysduringtheapplicableObservationPeriod,thepershare
volume-weightedaveragepriceasdisplayedundertheheading“BloombergVWAP”onBloombergpage“OCUL<equity>AQR”(oritsequivalentsuccessorifsuchpageisnotavailable)inrespectoftheperiodfromthescheduledopenoftradinguntilthescheduledcloseoftradingoftheprimarytradingsessiononsuchTradingDay(orifsuchvolume-weightedaveragepriceisunavailable,themarketvalueofoneshareoftheCommonStockonsuchTradingDaydetermined,usingavolume-weightedaveragemethod,byanationallyrecognizedindependentinvestmentbankingfirmretainedforthispurposebytheCompany).The“DailyVWAP”shallbedeterminedwithoutregardtoafter-hourstradingoranyothertradingoutsideoftheregulartradingsessiontradinghours.
(xxiii)“Dollars ”or“$ ”meansUnitedStatesDollars.
(xxiv)“Effective Date ”shallhavethemeaningsetforthinSection4(c)(ii).
(xxv)“Exchange Act ”meanstheSecuritiesExchangeActof1934,asamended.
(xxvi)“Holder Conversion Date ”meansthedateofdeliveryofaConversionNoticepursuanttoSection4(a).
(xxvii)“Interest ”meansanyinterestaccruedonthePrincipalpursuanttothetermsofthisNoteandtheNotePurchaseAgreement.
(xxviii)“Issuance Date ”meansMarch1,2019,regardlessofanyexchangeorreplacementhereof.
(xxix)“Last Reported Sale Price” oftheCommonStock(oranyothersecurityforwhichaclosingsalepricemustbedetermined)onanydatemeanstheclosingsalepricepershare(orifnoclosingsalepriceisreported,theaverageofthebidandaskpricesor,ifmorethanoneineithercase,theaverageoftheaveragebidandtheaverageaskprices)onthatdateasreportedincompositetransactionsfortheprincipalU.S.nationalorregionalsecuritiesexchangeonwhichtheCommonStock(orsuchothersecurity)istraded.IftheCommonStock(orsuchothersecurity)isnotlistedfortradingonaU.S.nationalorregionalsecuritiesexchangeontherelevantdate,the“Last Reported Sale Price ”shallbethelastquotedbidpricefortheCommonStock(orsuchothersecurity)intheover-the-countermarketontherelevantdateasreportedbyOTCMarketsGroupInc.orasimilarorganization.IftheCommonStock(orsuchothersecurity)isnotsoquoted,the“Last Reported Sale Price ”shallbetheaverageofthemid-pointofthelastbidandaskpricesfortheCommonStock(orsuchothersecurity)ontherelevantdatefromeachofatleastthreenationallyrecognizedindependentinvestmentbankingfirmsselectedbytheCompanyforthispurpose.The“Last Reported Sale Price ”shallbedeterminedwithoutregardtoafter-hourstradingoranyothertradingoutsideofregulartradingsessionhours.
4
![Page 36: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/36.jpg)
(xxx)“Make-Whole Consideration ”shallhavethemeaningsetforthinSection4(c)(i).
(xxxi)“Maturity Date ”meansMarch1,2026.
(xxxii)“Notice of Optional Redemption” shallhavethemeaningsetforthinSection3(b).
(xxxiii)“Observation Period ”withrespecttoanyNotesurrenderedforconversionmeans:(i)subjecttoclause(ii)below,the20
consecutiveTradingDaysbeginningon,andincluding,the22ndScheduledTradingDayimmediatelyprecedingtheConversionDateand(ii)iftherelevantConversionDateoccursonthesecondTradingDayimmediatelyprecedingtheMaturityDate,the20consecutiveTradingDaysbeginningon,andincluding,the22ndScheduledTradingDayimmediatelyprecedingtheMaturityDate.
(xxxiv)“Optional Redemption” shallhavethemeaningsetforthinSection3(a).
(xxxv)“Optional Redemption Date” shallhavethemeaningsetforthinSection3(b).
(xxxvi)“Optional Redemption Price” means,foranyNotes,orportionthereof,toberedeemedpursuanttoSection3(a),100%ofthePrincipalamountofsuchNotes,orportionthereof,plusaccruedandunpaidInterest,ifany,to,butexcluding,theOptionalRedemptionDate.
(xxxvii)“Ownership Cap ”shallhavethemeaningsetforthinSection4(a).
(xxxviii)“Person ”meansanindividual,acorporation,alimitedliabilitycompany,anassociation,apartnership,ajointventure,ajointstockcompany,atrust,anunincorporatedorganizationoragovernmentoragencyorapoliticalsubdivisionthereof.
(xxxix)“Physical Settlement ”shallhavethemeaningsetforthinSection4(e)(i).
(xl)“Principal ”meanstheoutstandingprincipalamountofthisNoteasofanydateofdetermination.
(xli)“Principal Trading Market ”meanstheTradingMarketonwhichtheCommonStockisprimarilylistedonandquotedfortrading,which,asoftheAgreementAgreement,shallbetheNasdaqGlobalMarket.
(xlii)“Repurchase Consideration ”shallhavethemeaningsetforthinSection13.
(xliii)“Required Note Holders ”meansHoldersofmorethan50%oftheaggregateprincipalamountoftheNotesoutstanding.
5
![Page 37: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/37.jpg)
(xliv)“Rule 144 ”meansRule144promulgatedbytheSECundertheSecuritiesAct.
(xlv)“Scheduled Trading Day ”meansadaythatisscheduledtobeaTradingDayonthePrincipalTradingMarketortheother
principalsecuritiesexchangeorothersecuritiesmarketorquotationsystemonwhichtheCommonStockisthenbeingtraded.IftheCommonStockisnotsolistedoradmittedfortrading,“ScheduledTradingDay”meansaBusinessDay.
(xlvi)“SEC ”meanstheSecuritiesandExchangeCommission.
(xlvii)“Securities Act ”meanstheSecuritiesActof1933,asamended.
(xlviii)“Settlement Amount ”shallhavethemeaningsetforthinSection4(e)(i).
(xlix)“Settlement Notice ”shallhavethemeaningsetforthinSection4(e)(i).
(l)“Shares ”meanssharesofCommonStock.
(li)“Specified Dollar Amount ”meansthemaximumcashamountper$1,000principalamountofNotestobereceiveduponconversionasspecifiedinthenoticespecifyingtheCompany’schosensettlementmethod.
(lii)“Stock Price ”shallhavethemeaningsetforthinSection4(c)(iii).
(liii)“Trading Day ”meansanydayonwhichtheCommonStockistradedforanyperiodonthePrincipalTradingMarketortheotherprincipalsecuritiesexchangeorothersecuritiesmarketorquotationsystemonwhichtheCommonStockisthenbeingtraded.
(liv)Trading Market ”meanswhicheveroftheNewYorkStockExchange,theNYSEAlternext(formerlytheAmericanStockExchange),theNasdaqGlobalSelectMarket,theNasdaqGlobalMarket,theNasdaqCapitalMarketortheOTCBulletinBoardonwhichtheCommonStockislistedorquotedfortradingonthedateinquestion.
(lv)“Transfer Delivery Period ”shallhavethemeaningsetforthinSection12(b).
2.PaymentTerms;Maturity.SimpleinterestontheunpaidprincipalbalanceofthisNotewillaccrueattherateof6.0%perannum.AccrualofinterestwillcommenceontheIssuanceDate,willcontinueuntilthisNoteisfullypaid,andwillbepayableinasingleinstallmentatmaturityassetforthbelow.Theinterestratewillbecomputedonthebasisoftheactualnumberofdayselapsedina365-dayyear.IfnotsoonerredeemedpursuanttoSection3,convertedpursuanttoSection4orrepurchasedpursuanttoSection13,theentireunpaidprincipalbalance,togetherwithallaccruedbutunpaidInterest,willbedueandpayableincashonMarch1,2026.AllpaymentsofInterestandPrincipalwillbemadeinlawfulmoneyoftheUnitedStatesofAmericaandwillbemadeprorataamongallHolders,withoutanydeductionby
6
![Page 38: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/38.jpg)
wayofset-off,counterclaim,orotherwise.AllpaymentswillbeappliedfirsttoInterestandthereaftertoPrincipal.AllpaymentswillbemadetotheHoldersattheirrespectiveaddressessetforthintheAgreementoratsuchotheraddressasisprovidedinwritingtotheCompany.
3.Redemption.
(a)ThisNoteshallnotberedeemablebytheCompanypriortoMarch1,2022.OnandafterMarch1,2022,theCompanymay,atitsoption,redeem(an“Optional Redemption ”)forcashalloranyportionofthisNote,attheOptionalRedemptionPrice,iftheLastReportedSalePriceoftheCommonStockhasbeenatleast130%oftheConversionRatethenineffectforatleasttwenty(20)TradingDays(whetherornotconsecutive)duringanythirty(30)consecutiveTradingDayperiod(includingthelastTradingDayofsuchperiod)endingon,andincluding,theTradingDayimmediatelyprecedingthedateonwhichtheCompanyprovidestheNoticeofOptionalRedemption(asdefinedbelow)inaccordancewiththisSection3(b).
(b)IncasetheCompanyexercisesitsOptionalRedemptionrighttoredeemallor,asthecasemaybe,anypartofthisNotepursuanttoSection3(a),theCompanyshallgivetheHolderfifteen(15)BusinessDays’priorwrittennoticeofanysuchOptionalRedemption(the“Notice of OptionalRedemption ”)andshallfixadateforredemption(the“Optional Redemption Date ”).UponreceiptofaNoticeofOptionalRedemption,theHoldermaysurrenderalloranyportionoftheirNotesforconversionpursuanttoSection4(a)atanytimepriortothecloseofbusinessontheScheduledTradingDayimmediatelyprecedingtheOptionalRedemptionDate.Afterthattime,therighttoconvertshallexpire,unlesstheCompanydefaultsinthepaymentoftheOptionalRedemptionPrice,inwhichcasetheHoldermayconvertitsNotesuntiltheOptionalRedemptionPricehasbeenpaidordulyprovidedfor.IffewerthanalloftheoutstandingNotesaretoberedeemed,theCompanyshallredeemtheNotesonaproratabasisamongallHolders.IfanyNoteselectedforpartialredemptionissubmittedforconversionpursuanttoSection4(a)inpartaftersuchselection,theportionoftheNotesubmittedforconversionshallbedeemed(sofarasmaybepossible)tobetheportionselectedforredemption.
4.ConversionRights.ThisNotemaybeconvertedonthetermsandconditionssetforthinthisSection4.
(a)ConversionatOptionoftheHolder.OnorafterthedatehereofandpriortothesecondTradingDayimmediatelyprecedingtheMaturityDate,theHoldershallbeentitledtoconvertalloranypartofthePrincipal(iftheportiontobeconvertedis$1,000principalamountoranintegralmultipleinexcessthereof)inaccordancewithSection4(e)attheConversionRate.Notwithstandinganythinghereintothecontrary,theCompanyshallnotissuetotheHolder,andtheHoldermaynotacquire,anumberofSharesuponconversionofthisNoteandtheCompanyshallnototherwiseissueanySharespursuantheretoortheNotePurchaseAgreement,totheextentthat,(i)uponsuchconversion,thenumberofSharesthenbeneficiallyownedbytheHolderanditsAffiliatesandanyotherPersonsorentitieswhosebeneficialownershipofCommonStockwouldbeaggregatedwiththeHolder’sforpurposesofSection13(d)oftheExchangeAct(includinganysharesheldbyany“group”ofwhichtheHolderisamember,butexcludingsharesbeneficiallyownedbyvirtueoftheownershipofsecuritiesorrightstoacquiresecuritiesthathavelimitationsontherighttoconvert,exerciseorpurchase
7
![Page 39: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/39.jpg)
similartothelimitationsetforthherein)wouldexceed19.99%ofthetotalnumberofSharesissuedandoutstanding(the“Ownership Cap ”)or(ii)suchissuance,whenaggregatedwithanyotherSharestheretoforeorsimultaneouslytherewithissuedtoorotherwisebeneficiallyownedbytheHolderanditsAffiliatesandanyotherPersonsorentitieswhosebeneficialownershipofCommonStockwouldbeaggregatedwiththeHolder’sforpurposesofSection13(d)oftheExchangeAct(includinganysharesheldbyany“group”ofwhichtheHolderisamember,butexcludingsharesbeneficiallyownedbyvirtueoftheownershipofsecuritiesorrightstoacquiresecuritiesthathavelimitationsontherighttoconvert,exerciseorpurchasesimilartothelimitationsetforthherein)wouldotherwiseresultina“changeofcontrol”oftheCompanywithinthemeaningofNasdaqListingRule5635(b).Forpurposeshereof,“group”hasthemeaningsetforthinSection13(d)oftheExchangeActandapplicableregulationsoftheSEC,andthepercentageheldbytheHoldershallbedeterminedinamannerconsistentwiththeprovisionsofSection13(d)oftheExchangeAct.UponthewrittenrequestoftheHolder,theCompanyshall,withintwo(2)BusinessDays,confirmorallyandinwritingtotheHolderthenumberofSharesthenoutstanding.Notwithstandinganythinghereintothecontrary,theCompanyshallhavenoobligationtotheHoldertopaythevalueoftheConversionSharesincash.ToexerciseaConversionpursuanttothisSection4(a)onanyHolderConversionDate,theHoldershalltransmitbyelectronicmail(orotherwisedeliver),forreceiptonorpriorto5:00p.m.NewYorkCitytimeonsuchdate,acopyofanexecutedconversionnoticeintheformattachedheretoasExhibitA(the“Conversion Notice ”)totheCompanyassetforthintheNotePurchaseAgreement.
(b)CorporateTransactionConversion.IfaCorporateTransactionoccursatanytime,theHoldershallhavetherightandoption,butnottheobligation,toconvertalloftheunpaidPrincipalattheConversionRateandreceiveacashpaymentequalto(i)theoutstandingaccruedbutunpaidInterestunderthisNoteto,butexcluding,theCorporateTransactionConversionDate(totheextentsuchdateoccurspriortotheMaturityDate)plus(ii)theMake-WholeConsiderationasdescribedinSection4(c)asfullandcompletesatisfactionofallobligationsunderthisNote.TheCompanywillprovideaCorporateTransactionNoticeinnoeventlaterthanfifteen(15)BusinessDaysfromwhentheCompanyfirstbecomesawareofsuchaCorporateTransaction.TheHoldermayelectaconversionpursuanttothisSection4(b)bydeliveringawrittennoticeofitselectiontoexerciseitsconversionright(the“Corporate Transaction ConversionNotice ”)notmorethanten(10)BusinessDaysafterreceivingtheCorporateTransactionNotice.SuchCorporateTransactionConversionNoticewillbebindingupondeliveryandwillconstituteanirrevocableelectionbytheHolder.
(c)Make-WholeConsideration.
(i)IfaCorporateTransactionoccurspriortotheMaturityDate,andtheHolderelectstoconvertitsNotesinconnectionwithsuchCorporateTransaction,theCompanyshall,underthecircumstancesdescribedbelow,includeasadditionalconsiderationanadditionalcashpaymentfortheNotessosurrenderedforconversion(the“Make-WholeConsideration”),asdescribedbelow.
(ii)TheamountofMake-WholeConsideration,ifany,shallbedeterminedbyreferencetothetablebelow,basedonthedateonwhichtheCorporate
Transactionoccurs(each,the“Effective Date ”)andtheprice(the“Stock Price ”)paid(ordeemedtobe
8
![Page 40: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/40.jpg)
paid)pershareoftheCommonStockintheCorporateTransaction.TheStockPriceshallbetheaverageoftheLastReportedSalePricesoftheCommonStockoverthefiveTradingDayperiodendingon,andincluding,theTradingDayimmediatelyprecedingtheCorporateTransaction.
(iii)TheStockPricessetforthinthecolumnheadingsofthetablebelowshallbeadjustedasofanydateonwhichtheConversionRateoftheNotesis
otherwiseadjusted.TheadjustedStockPricesshallequaltheStockPricesapplicableimmediatelypriortosuchadjustment,multipliedbyafraction,thenumeratorofwhichistheConversionRateimmediatelypriortosuchadjustmentgivingrisetotheStockPriceadjustmentandthedenominatorofwhichistheConversionRateassoadjusted.
(iv)ThefollowingtablesetsforththeamountofMake-WholeConsiderationper$1,000principalamountofNotespursuanttothisSection4(c)foreach
StockPriceandEffectiveDatesetforthbelow:
Stock Price
Effective Date
$3.61
$4.00
$5.00
$6.50
$7.00
$8.45
$10.00
$15.00
$20.00
$25.00
$50.00
$75.00
March1,2019
$ 444.61
$ 428.91
$ 387.36
$ 289.90
$ 282.77
$ 250.99
$ 224.63
$ 166.50
$ 135.17
$ 116.54
$ 58.39
$ 0.00
March1,2020
$ 444.61
$ 422.82
$ 365.85
$ 250.07
$ 243.92
$ 216.51
$ 193.77
$ 143.63
$ 116.60
$ 100.53
$ 50.37
$ 0.00
March1,2021
$ 444.61
$ 416.74
$ 344.34
$ 210.24
$ 205.08
$ 182.03
$ 162.91
$ 120.75
$ 98.03
$ 84.52
$ 42.34
$ 0.00
March1,2022
$ 444.61
$ 410.65
$ 322.82
$ 170.42
$ 166.23
$ 147.55
$ 132.05
$ 97.88
$ 79.46
$ 68.51
$ 34.32
$ 0.00
March1,2023
$ 444.61
$ 404.57
$ 301.31
$ 130.59
$ 127.38
$ 113.06
$ 101.19
$ 75.00
$ 60.89
$ 52.50
$ 26.30
$ 0.00
March1,2024
$ 444.61
$ 398.48
$ 279.80
$ 90.76
$ 88.53
$ 78.58
$ 70.33
$ 52.13
$ 42.32
$ 36.49
$ 18.28
$ 0.00
March1,2025
$ 444.61
$ 392.39
$ 258.28
$ 50.94
$ 49.68
$ 44.10
$ 39.47
$ 29.25
$ 23.75
$ 20.47
$ 10.26
$ 0.00
March1,2026
$ 444.61
$ 384.61
$ 230.76
$ 0.00
$ 0.00
$ 0.00
$ 0.00
$ 0.00
$ 0.00
$ 0.00
$ 0.00
$ 0.00
(v)TheexactStockPricesandEffectiveDatesmaynotbesetforthinthetableabove,inwhichcase:
(A)iftheStockPriceisbetweentwoStockPricesinthetableaboveortheEffectiveDateisbetweentwoEffectiveDatesinthetable,theamountof
Make-WholeConsiderationshallbedeterminedbyastraight-lineinterpolationbetweentheamountofMake-WholeConsiderationsetforthforthehigherandlowerStockPricesandtheearlierandlaterEffectiveDates,asapplicable,basedona365-dayyear;
(B)iftheStockPriceisgreaterthan$75.00pershare(subjecttoadjustmentinthesamemannerastheStockPricessetforthinthecolumnheadings
ofthetableabovepursuanttosubsection(iii)above),noMake-WholeConsiderationshallbepayable;and
9
(C)iftheStockPriceislessthan$3.61pershare(subjecttoadjustmentinthesamemannerastheStockPricessetforthinthecolumnheadingsof
thetableabovepursuanttosubsection(iii)above),noMake-WholeConsiderationshallbepayable.Notwithstandingtheforegoing,innoeventshalltheamountofMake-WholeConsiderationper$1,000principalamountofNotesexceed$444.61.
(d)ConversionRateAdjustment.IftheCompanyshall,atanytimeorfromtimetotime,(A)declareadividendontheCommonStockpayableinsharesofitscapitalstock(includingCommonStock),(B)subdividetheoutstandingCommonStockintoalargernumberofShares,(C)combinetheoutstandingCommonStockintoasmallernumberofsharesofitsCommonStock,or(D)issueanysharesofitscapitalstockinareclassificationoftheCommonStock(includinganysuchreclassificationinconnectionwithaconsolidationormergerinwhichtheCompanyisthecontinuingcorporation),thenineachsuchcase,theConversionRateineffectatthetimeoftherecorddateforsuchdividendoroftheeffectivedateofsuchsubdivision,combinationorreclassificationshallbeadjustedsothattheHolderofthisNoteuponconversionaftersuchdateshallbeentitledtoreceivetheaggregatenumberandkindofsharesofcapitalstockwhich,ifthisNotehadbeenconvertedimmediatelypriortosuchdate(withoutregardtotheOwnershipCap),suchholderwouldhaveowneduponsuchconversionandbeenentitledtoreceivebyvirtueofsuchdividend,subdivision,combinationorreclassification.Anysuchadjustmentshallbecomeeffectiveimmediatelyaftertherecorddateofsuchdividendortheeffectivedateofsuchsubdivision,combinationorreclassification.Suchadjustmentshallbemadesuccessivelywheneveranyeventlistedaboveshalloccur.IfadividendontheCommonStockpayableinsharesofitscapitalstock(includingCommonStock)isdeclaredandsuchdividendisnotpaid,theConversionRateshallagainbeadjustedtobetheConversionRate,ineffectimmediatelypriortosuchrecorddate(givingeffecttoalladjustmentsthatotherwisewouldberequiredtobemadepursuanttothisSection4(d)fromandaftersuchrecorddate).
(e)MechanicsofConversion.TheconversionofthisNoteshallbeconductedinthefollowingmanner:
(i)SettlementMethod.UponconversionofthisNotepursuanttoSection4(a)orSection4(b),theCompanyshallpayordeliver,asthecasemaybe,totheHolder,inrespectofeach$1,000principalamountofNotesbeingconverted,(A)cash(“Cash Settlement ”),(B)Shares,togetherwithcash,ifapplicable,inlieuofdeliveringanyfractionalshareofCommonStock(“Physical Settlement ”),or(C)acombinationofcashandShares,togetherwithcash,ifapplicable,inlieuofdeliveringanyfractionalShares(“Combination Settlement ”),atitselection,ineachcaseplusacashpaymentforaccruedandunpaidInterestto,butexcluding,thedateofsettlement.InrespectofanyConversionDate,theCompanyshalldeliveranotice(the“SettlementNotice ”)oftherelevantsettlementmethodinrespectofsuchConversionDate,theCompanyshalldeliversuchSettlementNoticetoconvertingHoldersnolaterthanthecloseofbusinessontheTradingDayimmediatelyfollowingtherelevantConversionDate.IftheCompanydoesnotelectasettlementmethodpriortothedeadlinesetforthintheimmediatelyprecedingsentence,theCompanyshallnolongerhavetherighttoelectCashSettlementorPhysicalSettlementandtheCompanyshallbedeemedtohaveelectedCombinationSettlement,andtheSpecifiedDollarAmountper$1,000principalamountofNotes
10
![Page 41: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/41.jpg)
shallbeequalto$1,000.SuchSettlementNoticeshallspecifytherelevantSettlementMethodandinthecaseofanelectionofCombinationSettlement,therelevantSettlementNoticeshallindicatetheSpecifiedDollarAmountper$1,000principalamountofNotes.IftheCompanydeliversaSettlementNoticeelectingCombinationSettlementbutdoesnotindicateaSpecifiedDollarAmountper$1,000principalamountofNotesinsuchSettlementNotice,theSpecifiedDollarAmountper$1,000principalamountofNotesshallbedeemedtobe$1,000.Thecash,Shares(andcashinlieuofanyfractionalshares)oracombinationofcashandSharesinrespectofanyconversionofNotes(the“Settlement Amount ”)shallbecomputedasfollows:
(A)iftheCompanyelectstosatisfysuchconversionbyPhysicalSettlement,theCompanyshalldelivertotheconvertingHolderinrespectofeach$1,000principalamountofNotesbeingconvertedanumberofSharesequaltotheConversionRateineffectontheConversionDate;
(B)iftheCompanyelectstosatisfysuchconversionbyCashSettlement,theCompanyshallpaytotheconvertingHolderinrespectofeach$1,000
principalamountofNotesbeingconvertedcashinanamountequaltothesumoftheDailyConversionValuesforeachofthetwenty(20)consecutiveTradingDaysduringtherelatedObservationPeriod;and
(C)iftheCompanyelectstosatisfysuchconversionbyCombinationSettlement,theCompanyshallpayordeliver,asthecasemaybe,inrespectofeach
$1,000principalamountofNotesbeingconverted,aSettlementAmountequaltothesumoftheDailySettlementAmountsforeachofthetwenty(20)consecutiveTradingDaysduringtherelatedObservationPeriod.
TheDailySettlementAmounts(ifapplicable)andtheDailyConversionValues(ifapplicable)shallbedeterminedbytheCompanypromptlyfollowingthelastdayoftheapplicableObservationPeriod.PromptlyaftersuchdeterminationoftheDailySettlementAmountsortheDailyConversionValues,asthecasemaybe,andtheamountofcashpayableinlieuofdeliveringanyfractionalshareofCommonStock,theCompanyshallnotifytheHolderoftheDailySettlementAmountsortheDailyConversionValues,asthecasemaybe,andtheamountofcashpayableinlieuofdeliveringfractionalShares.
(ii)DisputeResolution.InthecaseofadisputeastothedeterminationoftheConversionPriceorthearithmeticcalculationoftheConversionRateortheMake-WholeConsideration,theCompanyshallissuetotheHolderthenumberofConversionSharesandtheamountofcashthatisnotdisputedandshalltransmitanexplanationofthedisputeddeterminationsorarithmeticcalculationstotheHolderviaelectronicmailwithintwo(2)BusinessDaysofreceiptordeemedreceiptoftheHolder’sConversionNoticeorotherdateofdetermination.IftheHolderandtheCompanyareunabletoagreeuponthedeterminationoftheConversionPriceorarithmeticcalculationoftheConversionRatewithinone(1)BusinessDayofsuchdisputeddeterminationorarithmeticcalculationbeingtransmittedtotheHolder,thentheCompanyshallpromptly(andinanyeventwithintwo(2)BusinessDays)submitviafacsimile(A)thedisputeddeterminationoftheConversionPricetoanindependent,reputableinvestmentbankingfirmagreedtobytheCompanyandtheRequiredNoteHolders,or(B)thedisputedarithmeticcalculationoftheConversionRateortheMake-WholeConsiderationtothe
11
![Page 42: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/42.jpg)
Company’sindependentregisteredpublicaccountingfirm,asthecasemaybe.TheCompanyshalldirecttheinvestmentbankortheaccountingfirm,asthecasemaybe,toperformthedeterminationsorcalculationsandnotifytheCompanyandtheHolderoftheresultsnolaterthantwo(2)BusinessDaysfromthetimeitreceivesthedisputeddeterminationsorcalculations.Suchinvestmentbank’soraccountingfirm’sdeterminationorcalculation,asthecasemaybe,shallbebindinguponallpartiesabsentmanifesterror.
(iii)RecordHolder.ThePersonorPersonsentitledtoreceivetheConversionSharesissuableuponaconversionofthisNoteshallbetreatedforallpurposesasthelegalandrecordholderorholdersofsuchSharesupondeliveryoftheConversionNoticeviaelectronicmailorotherwiseinaccordancewiththetermshereof.
(iv)Book-Entry.Notwithstandinganythingtothecontrarysetforthherein,uponconversionorredemptionofthisNoteinaccordancewiththetermshereof,theHoldershallnotberequiredtophysicallysurrenderthisNotetotheCompanyunlessallofthePrincipalisbeingconvertedorredeemed.TheHolderandtheCompanyshallmaintainrecordsshowingthePrincipalconvertedorredeemedandthedatesofsuchconversionsorredemptionsorshallusesuchothermethod,reasonablysatisfactorytotheHolderandtheCompany,soasnottorequirephysicalsurrenderofthisNoteuponanysuchpartialconversionorredemption.Notwithstandingtheforegoing,ifthisNoteisconvertedorredeemedasaforesaid,theHoldermaynottransferthisNoteunlesstheHolderfirstphysicallysurrendersthisNotetotheCompany,whereupontheCompanywillforthwithissueanddeliverupontheorderoftheHolderanewNoteofliketenor,registeredastheHoldermayrequest,representingintheaggregatetheremainingPrincipalrepresentedbythisNote.TheHolderandanyassignee,byacceptanceofthisNote,acknowledgeandagreethat,byreasonoftheprovisionsofthisparagraph,followingconversionorredemptionofanyportionofthisNote,thePrincipalofthisNotemaybelessthantheprincipalamountstatedonthefacehereof.
(f)Legends.
(i)RestrictiveLegend.TheHolderunderstandsthatuntilsuchtimeasthisNoteortheConversionShareshavebeenregisteredundertheSecuritiesActorotherwisemaybesoldpursuanttoRule144undertheSecuritiesActoranexemptionfromregistrationundertheSecuritiesActwithoutanyrestrictionastothenumberofsecuritiesasofaparticulardatethatcanthenbeimmediatelysold,thisNoteandtheConversionShares,asapplicable,maybeararestrictivelegendinsubstantiallythefollowingform(andastop-transferordermaybeplacedagainsttransferofthecertificatesforsuchsecurities):
“[THISSECURITYANDTHECOMMONSTOCKISSUABLEUPONCONVERSIONOFTHISSECURITY][THESESHARESOFCOMMONSTOCK]HAVENOTBEENREGISTEREDUNDERTHESECURITIESACTOF1933,ASAMENDED(THE“SECURITIESACT”),ORAPPLICABLESTATESECURITIESLAWS.THE[SECURITIES][COMMONSTOCK]MAYNOTBESOLD,TRANSFERREDORASSIGNEDINTHEABSENCEOFANEFFECTIVEREGISTRATIONSTATEMENTFORTHESECURITIESUNDERTHESECURITIESACT,ORPURSUANTTOANEXEMPTIONFROMREGISTRATIONUNDERTHESECURITIESACT.INTHECASEOFA
12
![Page 43: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/43.jpg)
TRANSACTIONEXEMPTFROMREGISTRATIONTHECOMPANYRESERVESTHERIGHTTOREQUIREANOPINIONOFCOUNSELSATISFACTORYTOITASTOTHEAVAILABILITYOFANYEXEMPTIONFROMTHEREGISTRATIONREQUIREMENTSOFTHESECURITIESACT.”
5.RepurchaseatHolder’sOptionUponaCorporateTransaction.
(a)Generally.IfaCorporateTransactionoccursatanytime,theHoldershallhavetherightandoption,butnottheobligation,tocause
theCompanytopurchaseontheCorporateTransactionRepurchaseDate(asdefinedbelow)alloranyportionoftheunpaidPrincipalamountofthisNote(the“Corporate Transaction Repurchase Option ”)thatisequalto$1,000oranintegralmultipleof$1,000inexcessthereof,onthedatespecifiedbytheCompany(the“Corporate Transaction Repurchase Date ”)thatisnotlessthanfifteen(15)BusinessDaysfollowingthedateoftheCorporateTransactionNoticeforapurchasepriceincash(the“Repurchase Consideration ”)equaltothesumof:(i)100%ofthePrincipalamountofthisNotetobepurchased;plus(ii)accruedandunpaidInterestthereon,tobutexcludingtheRepurchaseDate(totheextentsuchdateoccurspriortotheMaturityDate).
(b)RequiredNotices.TheCompanyshallpromptlyprovidetheHolderwiththeCorporateTransactionNotice,butinnoeventlaterthanfifteen(15)BusinessDaysfromwhentheCompanyfirstbecomesawareofsuchaCorporateTransaction.TheHoldermaydelivertotheCompanywrittennoticeofitselectiontoexerciseitsrepurchaseright(the“Corporate Transaction Repurchase Notice ”)onorbeforethecloseofbusinessontheBusinessDayimmediatelyprecedingtheCorporateTransactionRepurchaseDate.
(c)PaymentofConsideration.TheCompanyshallpaytotheHolderontheCorporateTransactionRepurchaseDate,theRepurchaseConsiderationbywiretransferofimmediatelyavailablefundsagainstthedeliverytotheCompanyofthisNote,andthisNoteshallbecancelledandretired;provided,however,thatifonlyaportionoftheprincipalamountofthisNoteisbeingpurchased,thentheCompanyshall,concurrentlywithsuchdelivery,dulyexecuteanddelivertotheHolderanewNoteofthesametenorasthisNote,butwithaprincipalamountequaltotheprincipalamountoftheportionofthisNotenotbeingpurchased.Notwithstandingtheforegoing,intheeventthataHolderexercisestheCorporateTransactionRepurchaseOptionandtheCompanyfailstopaytheRepurchaseConsiderationinfullduetotheCompanymaintaininginsufficientfundstopaysuchRepurchaseConsideration,(i)thisNoteandthethenoutstandingPrincipalplusallaccruedandunpaidInterestthereonshallremainoutstandinguntilthedatetheHolderreceivestheRepurchaseConsiderationinfull,(ii)InterestonthePrincipalshallcontinuetoaccrue(upuntiltheHolderreceivestheRepurchaseConsiderationinfull)and(iii)theHoldershallmaintainallofitsrightsandremediesundertheNoteDocuments.
6.NoRightsasaStockholder.ThisNotedoesnotbyitselfentitletheHoldertoanyvotingrightsorotherrightsasastockholderoftheCompany.IntheabsenceofconversionofthisNote,noprovisionsofthisNote,andnoenumerationhereinoftherightsorprivilegesoftheHolder,shallcausetheHoldertobeastockholderoftheCompanyforanypurpose.
13
![Page 44: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/44.jpg)
7.VotingRights.Exceptasrequiredbylaw,theHoldershallhavenovotingrightswithrespecttoanyoftheConversionSharesuntildeliveryof
theConversionShares.
8.Amendment;Waiver.ThetermsandprovisionsofthisNoteshallnotbeamendedorwaivedexceptinawritingsignedbytheCompanyandtheHolder.
9.Remedies,Characterizations,OtherObligations,BreachesandInjunctiveRelief.TheremediesprovidedinthisNoteshallbecumulativeandinadditiontoallotherremediesavailableunderthisNote,theNotePurchaseAgreement,atlaworinequity(includingadecreeofspecificperformanceand/orotherinjunctiverelief).Noremedycontainedhereinshallbedeemedawaiverofcompliancewiththeprovisionsgivingrisetosuchremedy,andnothinghereinshalllimittheHolder’srighttopursueactualdamagesforanyfailurebytheCompanytocomplywiththetermsofthisNote.TheCompanycovenantstotheHolderthatthereshallbenocharacterizationconcerningthisinstrumentotherthanasexpresslyprovidedherein.TheCompanyacknowledgesthatabreachbyitofitsobligationshereunderwillcauseirreparableharmtotheHolderandthattheremedyatlawforanysuchbreachmaybeinadequate.TheCompanythereforeagreesthat,intheeventofanysuchbreachorthreatenedbreach,theHoldershallbeentitled,inadditiontoallotheravailableremedies,toaninjunctionrestraininganybreach,withoutthenecessityofshowingeconomiclossandwithoutanybondorothersecuritybeingrequired.
10.SpecificShallNotLimitGeneral;Construction.NospecificprovisioncontainedinthisNoteshalllimitormodifyanymoregeneralprovisioncontainedherein.ThisNoteshallbedeemedtobejointlydraftedbytheCompanyandallpurchasersofNotespursuanttotheNotePurchaseAgreementandshallnotbeconstruedagainstanyPersonasthedrafterhereof.
11.FailureorIndulgenceNotWaiver.NofailureordelayonthepartoftheHolderintheexerciseofanypower,rightorprivilegehereundershalloperateasawaiverthereof,norshallanysingleorpartialexerciseofanysuchpower,rightorprivilegeprecludeotherorfurtherexercisethereoforofanyotherright,powerorprivilege.
12.Notices.WhenevernoticeisrequiredtobegivenunderthisNote,unlessotherwiseprovidedherein,suchnoticeshallbegiveninaccordancewithSection7.1oftheNotePurchaseAgreement.
13.RestrictionsonTransfer.
(a)RegistrationorExemptionRequired.ThisNotehasbeenissuedinatransactionexemptfromtheregistrationrequirementssetforthundertheSecuritiesAct.NoneoftheNoteortheConversionSharesmaybepledged,transferred,sold,assigned,hypothecatedorotherwisedisposedofexceptpursuanttoaneffectiveregistrationstatementoranexemptiontotheregistrationrequirementsoftheSecuritiesActandapplicablestatelaws.
(b)Assignment;Transfer.ThetermsandconditionsofthisNoteshallinuretothebenefitofandbebindingupontherespectivesuccessorsandassignsoftheCompanyandtheHolder.TheHoldermaysell,assign,pledgeorotherwisetransferthisNoteif:(i)theHoldershallhavedeliveredthree(3)days’priorwrittennoticetotheCompany,substantiallyintheformoftheAssignmentattachedheretoasExhibitB,indicatingthePersonorPersonstowhomthe
14
![Page 45: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/45.jpg)
NoteshallbeassignedandtherespectiveprincipalamountoftheNotetobeassignedtoeachassignee;(ii)otherthaninthecaseofanassignmentortransferpursuanttoaneffectiveregistrationstatementfiledwiththeSECcoveringthedispositionofthisNoteorpursuanttoRule144,theHoldershallhavedeliveredtotheCompanyalegalopinionreasonablyacceptabletotheCompanytotheeffectthattheNotetobetransferredmaybetransferredpursuanttoanexemptionfromregistrationundertheSecuritiesAct;and(iii)theHoldershallhaveotherwisecompliedwithSection6.6oftheNotePurchaseAgreement.TheCompanyshalleffecttheassignmentwithinthree(3)BusinessDays(the“Transfer Delivery Period ”),andshalldelivertotheassignee(s)designatedbytheHolderaNoteorNotesofliketenorandtermsfortheappropriateprincipalamount.ThisNoteandtherightsevidencedherebyshallinuretothebenefitofandbebindinguponthesuccessorsandpermittedassignsoftheHolder.TheprovisionsofthisNoteareintendedtobeforthebenefitofallHoldersfromtimetotimeofthisNote,andshallbeenforceablebyanysuchHolder.TheOwnershipCapshallremaininplaceuponassignmentofthisNote.
14.PaymentofCollection,EnforcementandOtherCosts.If(a)thisNoteisplacedinthehandsofanattorneyforcollectionorenforcementoriscollectedorenforcedthroughanylegalproceeding;or(b)anattorneyisretainedtorepresenttheHolderinanybankruptcy,reorganization,orreceivershipoftheCompanyorotherproceedingsaffectingCompanycreditors’rightsandinvolvingaclaimunderthisNote,thentheCompanyshallpaythecostsincurredbytheHolderforsuchcollection,enforcementoraction,includingreasonableattorneys’feesanddisbursements.
15.Cancellation.AfterallPrincipal,Interestandotheramountsatanytimeowedunder,oronaccountof,thisNotehavebeenpaidinfullorconvertedinaccordancewiththetermshereof,thisNoteshallautomaticallybedeemedcancelled,shallbesurrenderedtotheCompanyforcancellationandshallnotbereissued.
16.WaiverofNotice.Totheextentpermittedbylaw,theCompanyherebywaivesdemand,notice,presentment,protestandallotherdemandsandnoticesinconnectionwiththedelivery,acceptance,performance,defaultorenforcementofthisNoteandtheNotePurchaseAgreement.
17.GoverningLaw.Allquestionsconcerningtheconstruction,validity,enforcementandinterpretationofthisNoteshallbegovernedbyandconstruedandenforcedinaccordancewiththeinternallawsoftheStateofNewYorkwithoutregardtothechoiceoflawprinciplesthereof.TheCompanyagreesthatalllegalproceedingsconcerningtheinterpretations,enforcementanddefenseofthetransactionscontemplatedbythisNoteshallbecommencedexclusivelyinthestateandfederalcourtssittingintheCityofNewYork.TheCompanyherebyirrevocablysubmitstotheexclusivejurisdictionofthestateandfederalcourtssittingintheCityofNewYork,boroughofManhattanfortheadjudicationofanydisputehereunderorinconnectionherewithorwithanytransactioncontemplatedherebyordiscussedherein,andherebyirrevocablywaives,andagreesnottoassertinanysuit,actionorotherproceeding,anyclaimthatitisnotpersonallysubjecttothejurisdictionofanysuchcourt,thatsuchsuit,actionorproceedingisimproperorisaninconvenientvenueforsuchproceeding.TheCompanyherebyirrevocablywaivespersonalserviceofprocessandconsentstoprocessbeingservedinanysuchsuit,actionorotherproceedingbymailingacopythereofviaregisteredorcertifiedUnitedStates
15
![Page 46: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/46.jpg)
mailorovernightdelivery(withevidenceofdelivery)tosuchPartyattheaddressineffectfornoticestoitundertheNotePurchaseAgreementandagreesthatsuchserviceshallconstitutegoodandsufficientserviceofprocessandnoticethereof.Nothingcontainedhereinshallbedeemedtolimitinanywayanyrighttoserveprocessinanyothermannerpermittedbylaw.THECOMPANYHEREBYWAIVESALLRIGHTSTOATRIALBYJURY.
18.InterpretativeMatters.Unlessthecontextotherwiserequires,(a)allreferencestoSectionsorExhibitsaretoSectionsorExhibitscontainedinorattachedtothisNote,(b)eachaccountingtermnototherwisedefinedinthisNotehasthemeaningassignedtoitinaccordancewithgenerallyacceptedaccountingprinciplesconsistentlyappliedassetforthintheopinionsandpronouncementsoftheAccountingPrinciplesBoardandtheAmericanInstituteofCertifiedPublicAccountants,(c)wordsinthesingularorpluralincludethesingularandpluralandpronounsstatedineitherthemasculine,thefeminineorneutergendershallincludethemasculine,feminineandneuterand(d)theuseoftheword“including”inthisNoteshallbebywayofexampleratherthanlimitation.Ifastocksplit,stockdividend,stockcombinationorothersimilareventoccursduringanyperiodoverwhichanaveragepriceisbeingdetermined,thenanappropriateadjustmentwillbemadetosuchaveragetoreflectsuchevent.
19.Execution.APDForotherreproductionofthisNotemaybedeliveredbytheCompany,andanexecutedcopyofthisNotemaybedeliveredbytheCompanybye-mailorothersimilarelectronictransmissiondevicepursuanttowhichthesignatureoforonbehalfoftheCompanycanbeseen,andsuchexecutionanddeliveryshallbeconsideredvalid,bindingandeffectiveforallpurposes.TheCompanyherebyagreesthatitshallnotraisetheexecutionofPDForotherreproductionofthisNote,orthefactthatanysignaturewastransmittedbye-mailorothersimilarelectronictransmissiondevice,asadefensetotheCompany’sexecutionofthisNote.Notwithstandingtheforegoing,theCompanyshallberequiredtodeliveranoriginallyexecutedNotetotheHolder.
20.SubordinationAgreement.EachHolderofthisNote,whethertheinitialHolderonthedatehereoforanysubsequentHolderbyassignmentorothertransfer,acknowledgesandagreesthattherepaymentofthisNoteandsuchHolder’srightsandremedieshereunder,areinallrespectssubjecttothetermsoftheSubordinationAgreement.EachHolderfurther(a)acknowledgesthatithasreceivedacopyoftheSubordinationAgreementandagreestobeboundtherebyasifanoriginalsignatorytheretoasa“SubordinatedCreditor”and(b)irrevocablyappoints,designatesandauthorizesCap1LLC,oritsassignee,asSubordinatedAgenttotakesuchactionorrefrainfromtakinganyactiononitsbehalfundertheprovisionsoftheSubordinationAgreementandtoexercisesuchpowersandperformsuchdutiesasareexpresslydelegatedtoitbythetermsofthisAgreement,togetherwithsuchpowersasarereasonablyincidentalthereto.
[Signaturepagefollows]
16
![Page 47: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/47.jpg)
INWITNESSWHEREOF,theCompanyhascausedthisNotetobedulyexecutedasofthedatefirstsetforthabove.
COMPANY:
OCULAR THERAPEUTIX, INC .
By: /s/DonaldNotmanName: DonaldNotmanTitle: ChiefFinancialOfficer
![Page 48: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/48.jpg)
Exhibit A
CONVERSION NOTICE
ReferenceismadetotheSeniorSubordinatedConvertibleNote(the“Note ”)ofOCULAR THERAPEUTIX, INC. ,aDelawarecorporation(the“
Company ”),intheoriginalprincipalamountof$37,500,000.InaccordancewithandpursuanttotheNote,theundersignedherebyelectstoconverttheConversionAmount(asdefinedintheNote)oftheNoteindicatedbelowintoSharesofCommonStock,parvalue$0.0001pershare(the“Common Stock ”),oftheCompany,asofthedatespecifiedbelow.DateofConversion:
AggregateConversionAmounttobeconvertedattheConversionPrice(asdefinedintheNote):Principal,applicablethereto,tobeconverted:PleaseissuetheCommonStockintowhichtheNoteisbeingconvertedinthefollowingnameandtothefollowingaddress:Issueto:EmailAddress:
Authorization:
By:
Title:
Dated:
DTCParticipantNumberandName(ifelectronicbookentrytransfer):AccountNumber(ifelectronicbookentrytransfer):
![Page 49: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/49.jpg)
Exhibit B
ASSIGNMENT
(Tobeexecutedbytheregisteredholder
desiringtotransfertheNote)
FORVALUERECEIVED,theundersignedholderoftheattachedSeniorSubordinatedConvertibleNote(the“Note ”)herebysells,assignsandtransfersuntothepersonorpersonsbelownamedtherighttoreceivetheprincipalamountof$fromOcularTherapeutix,Inc.,aDelawarecorporation,evidencedbytheattachedNoteanddoesherebyirrevocablyconstituteandappointattorneytotransferthesaidNoteonthebooksoftheCompany,withfullpowerofsubstitutioninthepremises.Dated:,20[]
SignatureFillinfornewregistrationofNote:
Name
Address
Pleaseprintnameandaddressofassignee(includingzipcodenumber)
NOTICEThesignaturetotheforegoingAssignmentmustcorrespondtothenameaswrittenuponthefaceoftheattachedNoteineveryparticular,withoutalterationorenlargementoranychangewhatsoever.
![Page 50: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/50.jpg)
Exhibit 5.1
+12122308800(t)+12122308888(f)
wilmerhale.comApril1,2019OcularTherapeutix,Inc.15CrosbyDriveBedford,Massachusetts01730Re:RegistrationStatementonFormS-3LadiesandGentlemen:ThisopinionisfurnishedtoyouinconnectionwithaRegistrationStatementonFormS-3(the“RegistrationStatement”)filedwiththeSecuritiesandExchangeCommission(the“Commission”)undertheSecuritiesActof1933,asamended(the“SecuritiesAct”),fortheregistrationofanaggregateof9,574,021sharesofcommonstock,$0.0001parvaluepershare(the“CommonStock”),ofOcularTherapeutix,Inc.,aDelawarecorporation(the“Company”),including3,804,788sharesoftheCompany’sCommonStockcurrentlyissuedandoutstanding(the“InitialCommonShares”)and5,769,233sharesoftheCompany’sCommonStockissuableupontheconversionofoutstandingseniorsubordinatedconvertiblenotes(the“ConversionShares”andtogether,withtheInitialCommonShares,the“Shares”)heldbyCap1LLC(the“SellingStockholder”).AlloftheSharesarebeingregisteredonbehalfoftheSellingStockholder.WeareactingascounselfortheCompanyinconnectionwiththeregistrationforresaleoftheShares.WehaveexaminedandrelieduponcopiesoftheRegistrationStatement,asfiledwiththeCommission,includingtheexhibitsthereto.WehavealsoexaminedandreliedupontheRestatedCertificateofIncorporationoftheCompany(asamendedorrestatedfromtimetotime);theAmendedandRestatedBy-lawsoftheCompany(asamendedorrestatedfromtimetotime);recordsofmeetingsandactionsofstockholdersandoftheBoardofDirectorsoftheCompany,includingcommitteesthereof,asprovidedtousbytheCompany;certificatesofrepresentativesoftheCompany;certificatesofpublicofficials;andsuchotherdocuments,instrumentsandcertificatesaswehavedeemednecessaryasabasisfortheopinionhereinafterexpressed.
![Page 51: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/51.jpg)
Inourexaminationoftheforegoingdocuments,wehaveassumedthegenuinenessofallsignatures,thelegalcapacityofallsignatories,theauthenticityofalldocumentssubmittedtousasoriginals,theconformitytooriginaldocumentsofalldocumentssubmittedtousascopies,theauthenticityofsuchoriginaldocuments,andthecompletenessandaccuracyofthecorporaterecordsandstockbooksoftheCompanyprovidedtousbytheCompany.Ouropinionbelow,insofarasitrelatestotheSharesbeingfullypaid,isbasedsolelyonacertificateoftheChiefFinancialOfficeroftheCompanyconfirmingtheCompany’sreceiptoftheconsiderationcalledforbytheapplicableresolutionsauthorizingtheissuanceofsuchShares.Weassumethattheappropriateactionwillbetaken,priortotheofferandsaleoftheShares,toregisterandqualifytheSharesforsaleunderallapplicablestatesecuritiesor“bluesky”laws.WeexpressnoopinionhereinastothelawsofanystateorjurisdictionotherthantheGeneralCorporationLawoftheStateofDelawareandthefederallawsoftheUnitedStatesofAmerica.Inaddition,weexpressnoopinionandmakenostatementhereinwithrespecttotheantifraudlawsofanyjurisdiction.Baseduponandsubjecttotheforegoing,weareoftheopinionthat(i)theInitialCommonShareshavebeendulyauthorizedandarevalidlyissued,fullypaidandnonassessableand(ii)theConversionShares,whenissuedanddeliveredupontheconversionoftheseniorsubordinatedconvertiblenotesissuedbytheCompanyinaccordancewiththetermsofsuchnotes,willbedulyauthorized,validlyissued,fullypaidandnonassessable.ItisunderstoodthatthisopinionistobeusedonlyinconnectionwiththeofferandsaleoftheShareswhiletheRegistrationStatementisineffect.Pleasenotethatweareopiningonlyastothemattersexpresslysetforthherein,andnoopinionshouldbeinferredastoanyothermatters.Thisopinionisbaseduponcurrentlyexistingstatutes,rules,regulationsandjudicialdecisions,andwedisclaimanyobligationtoadviseyouofanychangeinanyofthesesourcesoflaworsubsequentlegalorfactualdevelopmentswhichmightaffectanymattersoropinionssetforthherein.WeherebyconsenttothefilingofthisopinionwiththeCommissionasanexhibittotheRegistrationStatementinaccordancewiththerequirementsofItem601(b)(5)ofRegulationS-KundertheSecuritiesActandtotheuseofournamethereinandintherelatedprospectusunderthecaption“LegalMatters.”Ingivingsuchconsent,wedonotherebyadmitthatweareinthecategoryofpersonswhoseconsentisrequiredunderSection7oftheSecuritiesActortherulesandregulationsoftheCommission.
![Page 52: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/52.jpg)
Verytrulyyours,
WILMERCUTLERPICKERINGHALEANDDORRLLP
By: /s/BrianA.Johnson
BrianA.Johnson,aPartner
![Page 53: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/53.jpg)
QuickLinks--Clickheretorapidlynavigatethroughthisdocument
Exhibit23.1
CONSENTOFINDEPENDENTREGISTEREDPUBLICACCOUNTINGFIRM
WeherebyconsenttotheincorporationbyreferenceinthisRegistrationStatementonFormS-3ofOcularTherapeutix,Inc.ofourreportdatedMarch7,2019relatingtothefinancialstatements,whichappearsinOcularTherapeutixInc.'sAnnualReportonForm10-KfortheyearendedDecember31,2018.Wealsoconsenttothereferencetousundertheheading"Experts"insuchRegistrationStatement.
/s/PricewaterhouseCoopersLLPBoston,MassachusettsApril1,2019
![Page 54: OCULAR THERAPEUTIX, INC · OCULAR THERAPEUTIX, INC FORM S-3 (Securities Registration Statement (simplified form)) Filed 04/01/19 Address 24 CROSBY DRIVE BEDFORD, MA, 01730 Telephone](https://reader036.vdocuments.mx/reader036/viewer/2022071008/5fc5e38680e2a37c1f4bce6a/html5/thumbnails/54.jpg)
QuickLinks
Exhibit23.1
CONSENTOFINDEPENDENTREGISTEREDPUBLICACCOUNTINGFIRM